2021 European Heart Rhythm Association
Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

Jan Steffel1*, Ronan Collins2, Matthias Antz3, Pieter Cornu4, Lien Desteghe5,6, Karl Georg Haeusler7, Jonas Oldgren8, Holger Reinecke9, Vanessa Roldan-Schilling10, Nigel Rowell11, Peter Sinnaeve12, Thomas Vanasse12, Tatjana Potpara13, A. John Camm14, and Hein Heidbüchel5,6

External reviewers: Gregory Y. H. Lip (review coordinator)15,16,17 Thomas Deneke18, Nikolaos Dagres19, Giuseppe Boriani20, Tze-Fan Chao21, Eue-Keun Choi22, Melanie True Hills23, Itamar de Souza Santos24,25, Deirdre A. Lane15,16,17, Dan Atar26,27, Boyoung Joung28, Oana Maria Cole15,16, and Mark Field15,16

1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich, Switzerland; 2Age-Related Health Care, Tallaght University Hospital / Department of Gerontology Trinity College, Dublin, Ireland; 3Department of Electrophysiology, Hospital Braunschweig, Braunschweig, Germany; 4Faculty of Pharmacy and Pharmacology, School of Medicine, University of Florence, Florence, Italy; 5Division of Cardiology, Antwerp University and University Hospital, Antwerp, Belgium; 6Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; 7Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany; 8Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 9Department of Cardiology I - Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Münster, Germany; 10University of Murcia, Murcia, Spain; 11Middlesbrough, UK; 12Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; 13School of Medicine, Belgrade University, Belgrade, Serbia; 14Cardiology Clinical Academic Group, Molecular & Clinical Sciences Institute, St George’s University, London, UK; 15Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, UK; 16Liverpool Heart & Chest Hospital, Liverpool, UK; 17Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark; 18Clinic for Interventional Electrophysiology, Heart Center RHON-KLINIKUM Campus Bad Neustadt, Bad Neustadt an der Saale, Germany; 19Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany; 20Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy; 21Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich, Switzerland; 22Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; 23StopAfib.org, PO Box 541, Greenwood, TX 76246-0541, USA; 24Centro de Pesquisa Clínica e Epidemiológica, Hospital Universitário, Universidade de São Paulo, São Paulo, Brazil; 25Institute of Clinical Medicine and Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan; 26Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway; 27Institute of Clinical Sciences, University of Oslo, Oslo, Norway; and 28Yonsei University College of Medicine, Cardiology Department, Seoul, Republic of Korea

Keywords
NOACs • DOACs • apixaban • dabigatran • edoxaban • rivaroxaban

Table of Content

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations</td>
<td>2</td>
</tr>
<tr>
<td>Introduction</td>
<td>3</td>
</tr>
<tr>
<td>NOAC eligibility and dosing</td>
<td>4</td>
</tr>
<tr>
<td>Practical considerations for initiation and follow-up</td>
<td>7</td>
</tr>
<tr>
<td>Pharmacokinetics and drug–drug interactions of NOACs</td>
<td>10</td>
</tr>
<tr>
<td>NOACs in patients with chronic kidney disease or advanced liver disease</td>
<td>15</td>
</tr>
<tr>
<td>NOAC plasma level measurements: Technical approach, indications, pitfalls</td>
<td>22</td>
</tr>
<tr>
<td>Management of bleeding under NOAC therapy</td>
<td>26</td>
</tr>
<tr>
<td>Patients requiring an urgent surgical intervention</td>
<td>29</td>
</tr>
<tr>
<td>Patients undergoing a planned invasive procedure, surgery, or ablation</td>
<td>30</td>
</tr>
<tr>
<td>Patients with atrial fibrillation and coronary artery disease</td>
<td>35</td>
</tr>
<tr>
<td>Cardioversion in a NOAC-treated patient</td>
<td>39</td>
</tr>
<tr>
<td>AF patients presenting with acute stroke while on NOACs</td>
<td>40</td>
</tr>
<tr>
<td>NOACs in advanced age and frailty</td>
<td>43</td>
</tr>
<tr>
<td>NOACs in high- and low body weights</td>
<td>46</td>
</tr>
<tr>
<td>NOACs in other special populations</td>
<td>48</td>
</tr>
<tr>
<td>NOACs in patients with atrial fibrillation and malignancy</td>
<td>50</td>
</tr>
<tr>
<td>Optimizing dose adjustments of vitamin-K antagonists</td>
<td>51</td>
</tr>
</tbody>
</table>

* Corresponding author. Tel: +41 44 255 21 21. E-mail address: j.steffel@gmx.ch
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACS</td>
<td>Acute coronary syndrome</td>
</tr>
<tr>
<td>ACT</td>
<td>Activated clotting time</td>
</tr>
<tr>
<td>AED</td>
<td>Antiepileptic drugs</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>AFIRE</td>
<td>Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease</td>
</tr>
<tr>
<td>AMPLIFY</td>
<td>Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy</td>
</tr>
<tr>
<td>ANNEXA-4</td>
<td>Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors</td>
</tr>
<tr>
<td>aPCC</td>
<td>Activated prothrombin complex concentrates</td>
</tr>
<tr>
<td>aPTT</td>
<td>Activated partial thromboplastin time</td>
</tr>
<tr>
<td>ARISTOTLE</td>
<td>Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation</td>
</tr>
<tr>
<td>ATLANTIS</td>
<td>Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic Ischemic and Hemorrhagic Events after Trans-Aortic Valve Implantation for Aortic Stenosis</td>
</tr>
<tr>
<td>ATLAS</td>
<td>Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome—Thrombolysis in Myocardial Infarction</td>
</tr>
<tr>
<td>AUB</td>
<td>Abnormal uterine bleeding</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the curve</td>
</tr>
<tr>
<td>AUGUSTUS</td>
<td>Apixaban Versus Vitamin K Antagonist in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention,</td>
</tr>
<tr>
<td>AXADIA</td>
<td>A Safety Study Assessing Oral Anticoagulation With Apixaban Versus Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment</td>
</tr>
<tr>
<td>AXAFA-AFNET</td>
<td>Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy—Atrial Fibrillation Network</td>
</tr>
<tr>
<td>BCRP</td>
<td>Breast cancer resistance protein</td>
</tr>
<tr>
<td>BID</td>
<td>twice daily</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BMS</td>
<td>Bare metal stent</td>
</tr>
<tr>
<td>BRIDGE</td>
<td>Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery</td>
</tr>
<tr>
<td>CABG</td>
<td>Coronary artery bypass grafting</td>
</tr>
<tr>
<td>CAD</td>
<td>Coronary artery disease</td>
</tr>
<tr>
<td>CCS</td>
<td>Chronic coronary syndrome</td>
</tr>
<tr>
<td>CKD</td>
<td>Chronic kidney disease</td>
</tr>
<tr>
<td>CKD-EPI</td>
<td>Chronic Kidney Disease—Epidemiology Collaboration</td>
</tr>
<tr>
<td>CMB</td>
<td>Cerebral microbleeds</td>
</tr>
<tr>
<td>COMPASS</td>
<td>Cardiovascular Outcomes for People Using Anticoagulation Strategies</td>
</tr>
<tr>
<td>CORIDA</td>
<td>COntentration of Rivaroxaban, Dabigatran and Apixaban</td>
</tr>
<tr>
<td>COVID-19</td>
<td>Coronavirus Disease of 2019</td>
</tr>
<tr>
<td>CrCl</td>
<td>Creatinine clearance</td>
</tr>
<tr>
<td>CRN</td>
<td>Clinically relevant non-major bleeding</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>CV</td>
<td>Cardiovascular</td>
</tr>
<tr>
<td>CYP</td>
<td>Cytochrome P (CYP)</td>
</tr>
<tr>
<td>DAPT</td>
<td>Dual antiplatelet therapy</td>
</tr>
<tr>
<td>DDI</td>
<td>Drug–drug interaction</td>
</tr>
<tr>
<td>DES</td>
<td>Drug-eluting stent</td>
</tr>
<tr>
<td>DOAC</td>
<td>Direct oral anticoagulant</td>
</tr>
<tr>
<td>dTT</td>
<td>Diluted thrombin time</td>
</tr>
<tr>
<td>EACTS</td>
<td>European Association for Cardio-Thoracic Surgery</td>
</tr>
<tr>
<td>ECA</td>
<td>Ecarin chromogenic assay</td>
</tr>
<tr>
<td>EHRA</td>
<td>European Heart Rhythm Association</td>
</tr>
<tr>
<td>ELDERCARE-AF</td>
<td>Edoxaban low-dose for elder care AF patients</td>
</tr>
<tr>
<td>ELIMINATE-AF</td>
<td>Evaluation of Edoxaban compared with VKA in subjects undergoing catheter ablation of non-vascular atrial fibrillation</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>EMANATE</td>
<td>Eliquis evaluated in acute cardioversion compared to usual treatments for anticoagulation in subjects with NVAF</td>
</tr>
<tr>
<td>ENAVLE</td>
<td>Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement</td>
</tr>
<tr>
<td>ENGAGE AF-TIMI 48</td>
<td>Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48</td>
</tr>
<tr>
<td>ENSURE-AF</td>
<td>Edoxaban versus warfarin in subjects undergoing cardioversion of Atrial Fibrillation</td>
</tr>
<tr>
<td>ENTRUST-AF-PCI</td>
<td>Evaluation of the Safety and Efficacy of an Edoxaban-Based Compared to a Vitamin K Antagonist-Based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention With Stent Placement</td>
</tr>
<tr>
<td>ENVISAGE-TAVI</td>
<td>EdoxabaN Versus standard of care and their effects on clinical outcomes in pAtients havinG undergone Transcatheter Aortic Valve Implantation—Atrial Fibrillation</td>
</tr>
<tr>
<td>ESO</td>
<td>European Stroke Organization</td>
</tr>
<tr>
<td>ESC</td>
<td>European Society of Cardiology</td>
</tr>
<tr>
<td>FFP</td>
<td>Fresh frozen plasma</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular filtration rate</td>
</tr>
<tr>
<td>GI</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>GP</td>
<td>General practitioner</td>
</tr>
<tr>
<td>GRACE</td>
<td>Global Registry of Aacute Coronary Events</td>
</tr>
<tr>
<td>HCM</td>
<td>Hypertrophic cardiomyopathy</td>
</tr>
<tr>
<td>HCP</td>
<td>Healthcare provider</td>
</tr>
</tbody>
</table>
### Introduction

Non-vitamin K antagonist oral anticoagulants (NOACs) are considered by atrial fibrillation (AF) guidelines world-wide as the preferred choice of anticoagulants to prevent stroke in patients with AF. The term NOAC has been used for many years, is used by the current European Society of Cardiology (ESC) AF guidelines, and is widely recognized. Therefore, even though some authors refer to these drugs as ‘direct oral anticoagulants’ (DOACs), we prefer to continue to use the term NOAC. Ultimately, both terms are interchangeable when referring to the direct factor Xa inhibitors apixaban, edoxaban, and rivaroxaban as well as the direct thrombin inhibitor dabigatran.

NOACs have an improved efficacy/safety ratio and a predictable anticoagulant effect without the need for routine coagulation monitoring. However, the proper use of NOACs requires a carefully considered approach to many practical aspects. Each of the available NOACs is accompanied by the instructions for its proper use in many clinical situations (summary of product characteristics (SmPCs); patient cards; information leaflets for patients and health care providers).
physicians], but these are often slightly different (from drug to drug and from country to country), and physician education tools sometimes create confusion rather than clarity. Moreover, there are still several less well-researched aspects of NOAC use which are nonetheless relevant when these drugs are used by cardiologists, neurologists, geriatricians, general practitioners, and other healthcare providers (HCPs) in daily clinical practice. Based on these premises, the European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of NOACs. The first edition of the ‘Practical Guide’ was published in 2013,18 a first update was published in 20155; and a fully revised new version in 2018.10,10a The EHRA Practical Guide’s purpose is to provide support for safe and effective use of NOACs in daily practice, thereby supplementing ESC and other international guidelines mainly focusing on the scientific evidence for treatment of patients with AF with anticoagulation in general and of NOACs in particular.1–4

A writing group formulated practical answers to 16 clinical scenarios, based on updated information. During the conception and writing of the 2021 Practical Guide, a public call was made to all EHRA members as well as to the Heads of the National Cardiac Societies to submit their suggestions additions, corrections, modifications, etc. to the 2018 version of the Guide, and these have been incorporated wherever possible and appropriate. We thank all participants for their input, which has further improved this Guide. As in the previous iterations, the writing group was assisted by medical experts from the manufacturers of the NOACs, who provided assurance that the latest information on the different NOACs was evaluated and provided feedback on the alignment of the text with the approved European SmPCs. However, the final responsibility of this document resided entirely with the EHRA writing group. In some instances, the authors opted to advise options that do not fully align with all SmPCs, with the goal of providing more uniform and simple practical advice (e.g. on the start of NOACs after cessation of vitamin K antagonist (VKA); on advice after a missed or forgotten dose; on perioperative management and others). Obviously, local regulations and HCPs’ freedoms for prescription may vary and final responsibility of use lies with the prescribing healthcare professional.

An EHRA website—www.NOACforAF.eu—accompanies the Practical Guide. The Practical Guide is summarized in a Key Message booklet which can be obtained through EHRA and ESC, and which is available in the ‘EHRA Key Messages’ app. The website also provides EHRA members with a downloadable slide kit on the Practical Guide.

We hope that the current edition further improves the practical tool that EHRA envisioned. The authors realize that there will always be grey areas, unaddressed questions, gaps in knowledge, and hence areas of uncertainty and debate. Therefore, readers can continue to address their suggestions for change or improvement to the website or via EHRA.NOACguide2021@escardio.org.

NOAC eligibility and dosing

NOAC eligibility

NOACs are approved for stroke prevention in ‘non-valvular’ AF. Most SmPCs base eligibility on the CHADS2 score as it was commonly used in the phase III randomized clinical trials (RCTs). Given the consistent efficacy and safety, the indication for NOAC therapy has subsequently been broadened to patients qualifying for anticoagulation according to the CHA2DS2-VASc score,1 with some regional differences (e.g. Canada, Japan).

In order to avoid confusion, the use of the term ‘non-valvular’ is strongly discouraged in the ESC guidelines on the management of patients with AF, and reference is made to the specific underlying valvular heart disease.11,12 However, the term is still found in the individual SmPCs of each of the NOACs due to the original wording used in the exclusion criteria of the RCTs on which their regulatory approval was based. When it is used, the term ‘non-valvular AF’ refers to AF in the absence of a mechanical prosthetic heart valve or moderate to severe mitral stenosis (usually of rheumatic origin) (Table 1).11,12,13 which were exclusion criteria for all phase III NOAC vs. warfarin trials in AF. However, there is no RCT indicating that NOACs are less efficacious in patients with rheumatic mitral stenosis, and no rational base on which to hypothesize a differential response to NOACs vs. VKA.14 Indeed, the lack of eligibility only stems from exclusion of these patients from the pivotal RCTs. The INVICTUS-program investigating the use of VKA, Rivaroxaban or Aspirin in patients with rheumatic heart disease is currently ongoing (NCT02832531). Until these and other trials are completed, such patients should be treated with VKA as a standard of care. However, if therapy with VKA is truly impossible (e.g. no means of monitoring, no stable international normalized ratio (INR) even when using self-monitoring and management etc.) use of a NOAC may be an option which physicians could carefully evaluate, also in view of the lack of other studied, safe and effective alternatives, after informed consent of the patient regarding the off-label use in this situation.

In contrast, for AF in the context of mechanical mitral valve replacement, NOAC therapy should be discouraged unless new evidence reverses existing data that NOACs may be inferior to VKA for stroke prevention.15,16 Conversely, patients with degenerative valvular heart disease were variously included in the phase III trials, and NOACs demonstrated comparable relative efficacy and safety vs. warfarin in patients with vs. without valvular disease except for a higher risk of bleeding with rivaroxaban vs. warfarin in patients with valvular heart disease in a post hoc analysis of the ‘Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation’ (ROCKET-AF) trial.12,17,23 NOACs may therefore be used in patients with AF and most forms of valvular heart disease (Table 1).1,12

Until recently, oral anticoagulation (OAC) in patients with AF and biological valves or after valve repair constituted a grey area, even though these patients were included in some of the landmark NOAC trials.12,17,19,20 In the ‘Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation’ (RIVER) trial rivaroxaban was non-inferior to warfarin regarding the mean time until the combined endpoint of death, major cardiovascular events, or major bleeding at 12 months in 1005 patients with AF or flutter and a bioprosthetic mitral valve.24 Similarly, edoxaban was non-inferior in 220 patients included in the ‘Efficacy and Safety of edoxaban in Patients After Heart Valve Replacement’ (ENGAGE) trial (presented at ACC 2020). Today, NOACs hence appear as a valid option for the management of concomitant AF especially after the immediate 8–12 weeks after surgery.
For patients after transcatheter aortic valve implantation (TAVI), who have an indication for anticoagulation (e.g. AF), a small RCT of 157 patients comparing OAC alone with a combination of OAC plus clopidogrel, indicated a benefit from OAC alone in terms of reduced bleeding without compromising ischaemic events. A possibly even greater advantage was seen with the use of NOACs in this study (vs. VKA), but the study was underpowered to address this question. Observational data similarly found a lower rate of early thromboembolic- and bleeding events (as well as all-cause death in a more recent analysis) with NOACs vs. VKA after TAVI but residual confounding is likely. Dedicated trials are ongoing looking at the specific efficacy and safety of NOACs in this setting [e.g. ‘Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic Ischaemic and Hemorrhagic Events after Trans-Aortic Valve Implantation for Aortic Stenosis’ (ATLANTIS), ‘Edoxaban vs. standard of care and their effect on clinical outcomes in patients having TAVI—ENVI SAGE-TAVI’]. It is important to remember that while OAC (including NOAC) monotherapy may be considered after TAVI in patients with AF, OAC is currently not indicated in patients without an established indication for OAC in such patients.

In both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM), AF is associated with a high rate of thromboembolic- and bleeding events (as well as all-cause death in a more recent analysis) with NOACs vs. VKA after TAVI but residual confounding is likely. Dedicated trials are ongoing looking at the specific efficacy and safety of NOACs in this setting [e.g. ‘Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic Ischaemic and Hemorrhagic Events after Trans-Aortic Valve Implantation for Aortic Stenosis’ (ATLANTIS), ‘Edoxaban vs. standard of care and their effect on clinical outcomes in patients having TAVI—ENVI SAGE-TAVI’]. It is important to remember that while OAC (including NOAC) monotherapy may be considered after TAVI in patients with AF, OAC is currently not indicated in patients without an established indication for OAC in such patients.

Moreover, NOACs demonstrate a sustained efficacy over VKA also in other high-risk subgroups (e.g. patients with a high CHA2DS2-VASc score). As such, patients with HCM may be eligible for NOAC therapy.

NOACs are contraindicated in pregnancy, and reliable contraceptive measures need to be in place in women of child-bearing age before starting NOAC therapy (see Supplementary material online). Paediatric patients have been excluded from the pivotal stroke prevention RCTs and AF with need for OAC is rare in this population. NOAC therapy should be discouraged in children but can be considered in fully grown adolescents with body weight > 50 kg. Of note, body weight adjusted treatment with rivaroxaban has proven safe and effective for children with acute venous thromboembolism compared to standard anticoagulants over 3 months; dose-adjusted treatment with Dabigatran revealed a favourable safety profile for secondary prevention of venous thromboembolism in children 3 months to 18 years.

Patients with ‘non-valvular’ AF and antiphospholipid syndrome should be treated with VKA rather than NOACs, as a higher rate of thromboembolic and bleeding events was observed with rivaroxaban vs. warfarin in these patients.

### Table 1: Selected indications and contraindications for NOAC therapy in AF patients

<table>
<thead>
<tr>
<th>Condition</th>
<th>Eligibility for NOAC</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanical prosthesis valve</td>
<td>Contraindicated</td>
<td>Excluded from pivotal RCTs, data indicating worse outcome.</td>
</tr>
<tr>
<td>Moderate to severe mitral stenosis (usually rheumatic)</td>
<td>Contraindicated</td>
<td>Excluded from pivotal RCTs, little rationale for lesser efficacy and safety vs. VKA.</td>
</tr>
<tr>
<td>Other mild to moderate valvular disease (e.g. degenerative aortic stenosis, mitral regurgitation etc.) Bioprosthetic valve/valve repair (after &gt;3 months postoperative)</td>
<td>Included in NOAC trials</td>
<td>Data regarding efficacy and safety overall consistent with patients without valvular heart disease. Some data from NOAC RCTs, single RCT indicating non-inferiority to VKA. Patients without AF usually on ASA after 3–6 months post-surgery, hence NOAC therapy acceptable for stroke prevention if diagnosed with AF.</td>
</tr>
<tr>
<td>Severe aortic stenosis</td>
<td>Limited data (excluded in RE-LY)</td>
<td>No pathophysiologial rationale for lesser efficacy and safety. Most will undergo intervention.</td>
</tr>
<tr>
<td>Transcatheter aortic valve implantation</td>
<td>Acceptable</td>
<td>Single RCT + observational data, may require combination with APT.</td>
</tr>
<tr>
<td>Percutaneous transluminal aortic valvuloplasty</td>
<td>With caution</td>
<td>No prospective data, may require combination with APT.</td>
</tr>
<tr>
<td>Hypertrophic cardiomyopathy</td>
<td>Acceptable</td>
<td>No rational for lesser efficacy and safety vs. VKA.</td>
</tr>
</tbody>
</table>

Hatched, limited data; See text for details.

AF, atrial fibrillation; NOAC, non-vitamin K antagonist oral anticoagulant; RCT, randomized clinical trial; VKA, vitamin K antagonist.

Dosing

With four NOACs available in different dosages for different indications and with different dose reduction criteria, identification of the correct dose has become more complicated. Table 2 gives an overview of currently available NOACs and their doses in the different indications, including the relevant dose-reduction criteria.
### Table 2  OACs and approved/studied doses across indications

#### Stroke prevention in atrial fibrillation (SPAF)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Standard dose</th>
<th>Comments/dose reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apixaban</td>
<td>5 mg BID</td>
<td>2.5 mg BID if two out of three fulfilled: weight ≤60 kg, age ≥80 years, serum creatinine ≥133 μmol/L (1.5 mg/dL) (or single criterion: if CrCl 15–29 mL/min)</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>150 mg BID/110 mg BID</td>
<td>No pre-specified dose-reduction criteria in phase III trial of stroke prevention in atrial fibrillation (SPAF)</td>
</tr>
<tr>
<td>Edoxaban</td>
<td>60 mg QD</td>
<td>30 mg QD if: weight ≤60 kg or CrCl 15–49 mL/min or concomitant therapy with strong P-Gp inhibitor (see ‘Pharmacokinetics and drug-drug interactions of NOACs’ section)</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>20 mg QD</td>
<td>15 mg QD if CrCl ≤15–49 mL/min</td>
</tr>
</tbody>
</table>

⁎‘SmPc’ refers to European SmPc.

BID, twice daily; CrCl, creatinine clearance; GI, gastrointestinal; NOAC, non-vitamin K antagonist oral anticoagulant; QD, once daily.

### NOAC dosing in AF patients post-ACS/PCI (see ‘Patients with atrial fibrillation and coronary artery disease’ section)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Standard dose</th>
<th>Comments/dose reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apixaban</td>
<td>5 mg BID</td>
<td>Dose reduction as for SPAF</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>150 mg BID or 110 mg BID</td>
<td>110 mg as for SPAF⁎</td>
</tr>
<tr>
<td>Edoxaban</td>
<td>60 mg QD</td>
<td>Dose reduction as for SPAF</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>15 mg QD</td>
<td>Dose reduction to 10 mg QD if CrCl 30–49 mL/min</td>
</tr>
</tbody>
</table>

In addition to single/dual antiplatelet therapy, where applicable. See ‘Patients with atrial fibrillation and coronary artery disease’ section for details.

BID, twice daily; CrCl, creatinine clearance; QD, once daily; SPAF, stroke prevention in atrial fibrillation.

### Treatment of DVT/PE

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial therapy</th>
<th>Remainder of treatment phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apixaban</td>
<td>10 mg BID, 7 days</td>
<td>5 mg BID, no dose reduction</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>Heparin/LMWH</td>
<td>150 mg BID, no dose reduction⁎</td>
</tr>
<tr>
<td>Edoxaban</td>
<td>Heparin/LMWH</td>
<td>60 mg QD, same dose reduction as for SPAF (see above)</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>15 mg BID, 21 days</td>
<td>20 mg QD, no dose reduction⁴</td>
</tr>
</tbody>
</table>

BID, twice daily; GI, gastrointestinal; LMWH, low molecular weight heparin; QD, once daily; SPAF, stroke prevention in atrial fibrillation.

⁎Per SmPC: 110 mg BID if age ≥80 years, concomitant verapamil, increased risk of GI bleeding [based on pharmacokinetic/pharmacodynamic (PK/PD) analyses; not studied in this setting].

⁴Per SmPC: 15 mg if risk of bleeding outweighs risk for recurrent DVT and PE (based on PK/PD analyses; not studied in this setting).

### Long-term prevention of recurrent DVT/PE

<table>
<thead>
<tr>
<th>Drug</th>
<th>Standard dose</th>
<th>Comments/dose adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apixaban</td>
<td>2.5 mg BID</td>
<td>No pre-specified dose-reduction criteria in clinical trial of stroke prevention in atrial fibrillation (SPAF)</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>150 mg BID</td>
<td></td>
</tr>
<tr>
<td>Edoxaban</td>
<td>60 mg QD⁵</td>
<td></td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>10 mg QD</td>
<td></td>
</tr>
</tbody>
</table>

BID, twice daily; QD, once daily.

⁵SmPC: 110 mg BID if age ≥80 years, concomitant verapamil (both based on pharmacokinetics/pharmacodynamics analyses; not studied in this setting).

⁶Not specifically studied, follow-up data available up to 12 months in phase III trial.

⁷SmPC: 20 mg QD in patients at high risk of recurrence.
Even in settings with optimal patient education (see ‘Practical considerations for initiation and follow-up’ section) dosing errors are common in daily practice, and patients need to be informed on what to do in such cases. In order to provide a more uniform and simple practical advice, the writing group acknowledges that some of the below advice does not fully align with all European SmPCs.

**Missed dose**

A forgotten dose may be taken until half of the dosing interval has passed. Hence, for NOACs with a twice daily (BID) dosing regimen (i.e., intake every 12 h), a forgotten full dose can be taken up until 6 h after the scheduled intake. For NOACs with a once daily (QD) dosing regimen, a forgotten dose can be taken up until 12 h after the scheduled intake. After these time points, the dose should be skipped, and the next scheduled dose should be taken.

**Double dose**

For NOACs with a BID dosing regimen, the next planned dose (i.e., after 12 h) may be skipped, with the regular BID dosing regimen restarted 24 h after the double dose intake.

For NOACs with a QD dosing regimen, the patient should continue the normal dosing regimen, i.e. without skipping the next daily dose.

**Uncertainty about dose intake**

For NOACs with a BID dosing regimen, it is generally advisable to not take another tablet/capsule, but to continue with the regular dose regimen, i.e. starting with the next dose at the 12 h interval.

For NOACs with a QD dosing regimen, when thromboembolic risk is high (CHA2DS2-VASc ≥3), it may generally be advisable to take another tablet 6–8 h after the original (uncertain) intake and then continue the planned dose regimen. In case the thromboembolic risk is low (CHA2DS2-VASc ≤2) we advise to wait until the next scheduled dose.

---

**Practical considerations for initiation and follow-up**

**Choice of anticoagulant therapy and initiation**

**Indication for anticoagulation and choice between VKA and NOAC**

- After the indication for OAC is established, NOACs are preferred over VKAs in all NOAC-eligible AF patients (see ‘NOAC eligibility and dosing’ section).
- When starting a NOAC, knowledge of current kidney and liver function is required as all NOACs are eliminated to some extent via the kidneys, and renal function affects NOAC dosing. Importantly, kidney function should be assessed using the Cockcroft–Gault formula as it was used in the four pivotal phase III trial (see ‘NOACs in patients with chronic kidney disease or advanced liver disease’ section for details). Indeed, use of other formulas including ‘Modification of Diet in Renal Disease’ (MDRD)
and ‘Chronic Kidney Disease—Epidemiology Collaboration’ (CKD-EPI) may overestimate kidney function particularly in older patients and in those with low body weights.43
• A baseline haematological profile should be obtained for reference during future follow-up.
• Bleeding risk, as estimated using the HAS-BLED score, is not in itself a reason to deny OAC to AF patients at risk of stroke or reduce the dose of the NOAC. Instead, particularly patients at high bleeding risk (e.g. HAS-BLED ≥3) should have their modifiable bleeding risk factors identified and addressed,1,44 and should be scheduled for an earlier and more frequent clinical follow-up.45
• Similarly, frailty, cognitive decline and risk of falling should not generally be a reason not to anticoagulate patients. Care needs to be taken to minimize the risk of falling and to ensure optimal compliance and adherence. This topic is dealt with in detail in the ‘NOACs in advanced age and frailty’ section.

Choosing the type and dose of NOACs
With four NOACs available in different dosages for different indications and with different dose reduction criteria, identification of the correct dose has become more complicated and is one of the key challenges in the daily use and individualization of treatment (see ‘NOAC eligibility and dosing’ section). Local factors, such as regulatory approval, formulary restrictions, and the cost of therapy, may influence NOAC availability in specific healthcare settings.

All NOACs have been tested in large randomized prospective trials and have shown efficacy and safety of the respective agents. Testing of different doses, however, was carried out differently. In the ‘Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation’ (ARISTOTLE) trial (using apixaban) and ROCKET-AF (using rivaroxaban) trials, patients received a standard dose which was reduced in the presence of predefined patient characteristics.46,47 In contrast, in the ‘Randomized Evaluation of Long-Term Anticoagulation Therapy’ (RE-LY) trial (with dabigatran) and ‘Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48’ (ENGAGE AF-TIMI 48) trial (with edoxaban) both a lower and a higher dose were tested in fully powered patient cohorts (without further dose reduction for dabigatran, and with further dose reduction for edoxaban in certain patients).48,49 Dose reduction of NOACs is primarily recommended according to the published and approved dose reduction criteria (see ‘NOAC eligibility and dosing’ section)1 Whenever possible, the tested and approved dose of NOACs should be used to provide optimal benefit for the patient.

There is a wealth of published data to confirm that in daily clinical practice—i.e. outside the controlled clinical trial setting—NOACs are at least as safe and efficacious as warfarin.50-55 However, some patterns have emerged from large observational studies indicating a higher than anticipated off-label dosing of NOACs.51,56-60 This is related to the fact that HCPs mostly worry about the risk of bleeding (as an iatrogenic event), whereas the risk of a stroke is often viewed as a possible ‘natural course of the disease’. However, various large trials and observational series indicate that high-risk patients derive a particularly pronounced benefit from anticoagulation.47,49,51,69-71

Involving the patient into the decision process and discussing together the options of anticoagulation (‘shared decision making’) is key in order to adequately assess patients’ needs, as for patients—in contrast to physicians—the risk of stroke usually outweighs the risk of a bleed.72-74

In addition, it is important to consider co-medications, some of which may be contraindicated or result in unfavourable drug–drug interactions (see ‘Pharmacokinetics and drug–drug interactions of NOACs’ section). Also, patient age and frailty (see ‘NOACs in advanced age and frailty’ section), weight (see ‘NOACs in high- and low body weights’ section), renal function (see ‘NOACs in patients with chronic kidney disease or advanced liver disease’ section), and other comorbidities influence the choice. Proton pump inhibitors (PPIs) may be considered to reduce the risk for gastrointestinal (GI) bleeding and accompanying hospitalizations, especially in those with a history of GI bleeding or ulcer and patients requiring concomitant use of (dual) antiplatelet therapy.75-80 This gastroprotective effect was especially demonstrated in patients receiving antplatelet or VKA therapy,81,82 while data on the preventive effects in NOAC treated patients are limited.79 Decision aids are available to guide clinicians about which NOAC may be best suited for a specific target group.84-87

Practical considerations regarding adherence and persistence
Practical considerations to assure adherence and persistence with NOAC therapy are summarized in Figure 1 and discussed in the Supplementary material online. Figure 2 shows the EHRA NOAC card (details see Supplementary material online), Figure 3 shows the structured follow-up scheme of NOAC treated patients.

Organization of follow-up and continued care
The organization of follow-up and continued care is summarized in Figure 3 and Table 3, and is discussed in detail in the Supplementary material online.

Switching between anticoagulant regimens
Practical advice on how to switch between anticoagulant regimens is summarized in Figure 4 and discussed in detail in the Supplementary material online.

Special considerations for NOAC use during the ‘coronavirus disease of 2019’ (COVID-19) pandemic
In addition to the general preference of NOACs over VKA for stroke prevention in AF due to efficacy and safety,16 NOAC therapy comes with some potentially important practical advantages over VKA-based anticoagulation during the coronavirus disease of 2019 (COVID-19) pandemic, including the lack of necessity for frequent clinic/office visits for INR monitoring. Community teams for at home INR controls may equally be limited during these periods. As a result, both the individual’s risk for contracting the virus as well as the workload on the healthcare system would be reduced.

Nevertheless, NOAC therapy also comes with its inherent challenges necessitating a well-planned and executed follow-up scheme (Figure 3) to optimize efficacy and safety of the drugs (see above). Conversely, any ‘file and forget’ NOAC use needs to be avoided also
**Figure 2** The EHRA NOAC card. A patient information card is crucial, both for the patient (instructions on correct intake; contact information in case of questions) as for healthcare providers. This generic and universal card should document each visit, each relevant observation or examination, and any medication change. EHRA, European Heart Rhythm Association; NOAC, non-vitamin K antagonist oral anticoagulant.
during a high-tide pandemic situation. Unfortunately, this is particularly true for high-risk AF patients—who almost inevitably would also potentially be high-risk COVID-19 patients in case of exposure and infection, likely primarily due to concomitant risk factors and comorbidities.\textsuperscript{88–90} Careful and wise decision-making regarding the type of NOAC, dose and follow-up scheme is essential. Importantly, since plasma level assessment of NOACs or coagulation tests are not needed, large parts of the regular follow-up routine may be performed via telemonitoring, including assessment of any thromboembolic or bleeding events, side effects, adherence, clinical factors precipitating a relevant decline in renal function \textit{e.g.} dehydration, intercurrent illnesses, non-steroidal anti-inflammatory drug (NSAID) use, etc. By doing so, in-person consultation may be reduced to a minimum and only be scheduled if physical examination and/or blood sampling (renal function, haemoglobin etc.) is required. Nevertheless, clear communication, ideally in writing \textit{e.g.} with Email follow-up is key in order to avoid misunderstandings in these frequently older patients not accustomed to this way of consultation.

If patients on NOACs are infected with COVID-19 and particularly in case of severe infection requiring hospitalization, increasing evidence indicates a benefit for continuing anticoagulation to stave off COVID-19 complications.\textsuperscript{91} However, clinical deterioration (particularly of renal function) as well as administration of concomitant medication (see ‘Pharmacokinetics and drug–drug interactions of NOACs’ section) needs to be carefully observed and therapy adjusted accordingly. Assessment via a multidisciplinary expert team including cardiologist, intensive care specialists, haematologists, neurologist etc. and, if in doubt, conversion to low-molecular or unfractionated heparin (UFH) is advisable. Further specific guidance can be found in the ‘ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic’.\textsuperscript{92}

Covid-19 vaccines are usually administered by intramuscular (i.m.) injection. In patients on NOACs it is advisable to follow the scheme for ‘minor risk’ interventions as outlined in the ‘Patients undergoing a planned invasive procedure, surgery, or ablation’ section (as well as in the Supplementary material online):

\begin{itemize}
  \item Leave out the morning dose of the NOAC prior to i.m. injection;
  \item Use a fine-gauge needle for injection;
  \item Apply firm pressure for 2–5 min after the injection;
  \item In QD NOACs: take the left-out morning dose 3 h after the injection (esp. in case of high stroke risk and QD NOAC); and
  \item In BID NOACs: re-start NOAC with the next scheduled dose.
\end{itemize}

\section*{Pharmacokinetics and drug–drug interactions of NOACs}

Treatment with VKAs requires careful consideration of multiple food- and drug–drug interactions (DDIs). Despite fewer interactions with NOACs, physicians need to consider the pharmacokinetic interactions of accompanying drugs and comorbidities when prescribing NOACs. This section aims to provide a simple, non-exhaustive guide

\begin{figure}
\centering
\includegraphics[width=\textwidth]{image}
\caption{Initiation and structured follow-up of patients on NOACs. It is crucial to ensure a structured follow-up of patients on NOACs. The anticoagulation card, as proposed in Figure 2, is intended to document each visit so that every person following up on the patient is well-informed. Moreover, written communication between different healthcare providers is required to inform them about the follow-up plan and execution. AF, atrial fibrillation; CrCl, creatinine clearance; GP, General Practitioner; NOAC, non-vitamin K antagonist oral anticoagulant.}
\end{figure}

\begin{table}
\centering
\begin{tabular}{|c|c|}
\hline
\textbf{Initiator of anticoagulant treatment} & \\
\hline
- Indication (contra-indication?) for anticoagulation & \\
- Baseline blood works, incl. hemoglobin, renal / liver function, full coagulation panel & \\
- Choice of anticoagulant and correct dose & \\
- Education and handover of anticoagulation card & \\
- Organization of follow-up (when, where, by whom, what?) & \\
\hline
\textbf{Regular follow-up: GP, cardiologist, anticoagulation / AF clinic, ...} & \\
\hline
\textit{may be performed via phone / video call, particularly if in-person visit is not possible or deemed risky, e.g., during Covid-19 pandemic} & \\
- Thromboembolic / bleeding events? & \\
- Side effects? & \\
- Adherence (discussion, explanation, remaining pills, NOAC card, ...) & \\
- Change in co-medication (incl. over-the-counter drugs?) & \\
- Need for blood sampling? Hemoglobin, renal function, coagulation panel etc. & \\
- Re-assessment of CHA\textsubscript{2}DS\textsubscript{2}-VASc and HAS-BLED score & \\
- Modifiable stroke- and bleeding risk factor assessment and -improvement & \\
- Re-assessment of optimal NOAC and correct dosing & \\
\hline
\end{tabular}
\end{table}
to deal with such situations. However, every patient may require more specific consideration, especially when a combination of interfering factors is present. The considerations on DDIs given in this chapter are based on extensive research using Stockleys Drug Interactions (https://about.medicinescomplete.com/publication/stockleys-drug-interactions/), UpToDate (https://www.uptodate.com/home/drugs-drug-interaction), the Phil database (https://philpb.be/nl-BE/product/2756153), as well as numerous published studies.

Table 3 Checklist during follow-up contacts of AF patients on anticoagulation

<table>
<thead>
<tr>
<th>Interval</th>
<th>Comments</th>
</tr>
</thead>
</table>
| 1. Adherence | Each visit  
• Instruct patient to bring NOAC card and complete list of medication: make note and assess adherence.  
• Re-educate on importance of strict intake schedule.  
• Inform about adherence aids (special boxes; smartphone applications; ...).  
Consider specific adherence-measuring interventions (see ‘Practical considerations for initiation and follow-up’ section)  
• Inform about minor bleeding (gum, epistaxis, small ecchymosis) and instruct not to skip any dose without prior consultation  
• Assess cognitive function |
| 2. Thromboembolism | Each visit  
• Systemic circulation (TIA, stroke, peripheral).  
• Deep vein thrombosis, pulmonary embolism |
| 3. Bleeding | Each visit  
• For every bleeding: Look for reason. Cancer? Ulcer? Other causes, lesions etc.? Treatment or prevention possible?  
• ‘Nuisance’ bleeding: Reason? Treatment/prevention (see above)?  
• Assess impact on quality of life. |
| 4. Other side effects | Each visit  
• Carefully assess relation with NOAC: decide for continuation (and motivate) or change NOAC. |
| 5. Co-medications | Each visit  
• Prescription drugs; over-the-counter drugs.  
• Careful interval history (also temporary use, e.g. NSAIDs) |
| 6. Blood sampling (including haemoglobin, renal, and liver function) | Yearly  
• In all patients except those below  
4-monthly  
• ≥75 years (especially if on dabigatran), or frail.  
Variable  
• If renal function CrCl ≤60 mL/min:  
• CrCl/10 = minimum recheck interval (in months).  
If needed  
• In case of intercurrent conditions, especially with potential impact on renal or hepatic function (e.g. infection, NSAID use, dehydration etc.). |
| 7. Re-assess stroke risk | Each visit  
• CHA2DS2-VASc score, as recommended by current guidelines¹ |
| 8. Assessing and minimizing modifiable risk factors for bleeding | Each visit  
• As recommended by current guidelines¹  
• Particularly:  
• Uncontrolled hypertension (systolic > 160 mmHg)  
• Medication predisposing for bleeding (e.g. aspirin, NSAIDs)  
• Labile INR (if on VKA)  
• Excessive alcohol intake  
• Falls |
| 9. Assessing for optimal NOAC and correct dosing¹ | Each visit  
• Especially based on the above, re-assess whether  
• The chosen NOAC is the best for the patient  
• The chosen dose is correct |

AF, atrial fibrillation; CrCl, creatinine clearance; INR, international normalized ratio; NOAC, non-vitamin K antagonist oral anticoagulant; NSAID, non-steroidal anti-inflammatory drug; TIA, transient ischaemic attack; VKA, vitamin K antagonist.

¹ For frequency of visits: see Figure 3.
reviews, and case reports. Knowledge regarding interactions (with effect on plasma levels and/or on clinical effects of NOAC drugs) is expanding, so that new information is likely going to modify existing advice.

The absorption, distribution, metabolism, and excretion of the different NOACs are summarized in Table 4 and Figure 5. An important interaction mechanism for most NOACs consists of significant GI resecretion over a P-glycoprotein (P-gp) transporter after absorption in the gut. P-gp is also involved in active renal secretion of NOACs. Competitive inhibition of the P-gp pathway will result in increased plasma levels, which needs to be considered since many drugs used in AF patients are P-gp inhibitors (e.g. verapamil, dronedarone, amiodarone, ranolazine, and quinidine). CYP3A4-type cytochrome P450-dependent elimination is relevantly involved in the hepatic clearance of rivaroxaban and apixaban. Strong cytochrome P (CYP) 3A4 inhibition or induction may affect plasma concentrations, and should be evaluated in context (see Tables 5–9 and colour coding, discussed below). Non-metabolic clearance of apixaban is diverse (including excretion of the unchanged compound by >50%). In general, NOAC use is not advisable in combination with drugs that are strong inhibitors of both P-gp and/or CYP3A4. Conversely, strong inducers of P-gp and/or CYP3A4 (such as rifampicin, carbamazepine, etc.) will markedly reduce NOAC plasma levels; concomitant use with NOACs should be avoided or used with great caution and surveillance.

Specific dosing algorithms for the different NOACs have been evaluated in large phase III clinical RCTs and resulted in documented efficacy and safety of the respective agents. Of note, only one phase III study prospectively used concomitant therapy with certain drugs as a dose reduction criterion (dose reduction of edoxaban in ENGAGE-AF in patients treated with potent P-gp inhibitors verapamil, quinidine, or dronedarone). Dose reduction of all NOACs is primarily recommended along the published dose reduction criteria (see ‘NOAC eligibility and dosing’ section, Table 2). Whenever possible, the tested and approved dosing regimen of NOACs should be used. However, there may be a clinical rationale for using a lower dose of a NOAC in patients with a particularly high bleeding risk and/or when a higher plasma level of the drug can be anticipated based on a combination of factors even if the label-recommended criteria for dose reduction are not fulfilled. Prospective clinical trial data only exist for ‘lower doses’ of dabigatran (110 mg BID) and edoxaban (lower dose edoxaban regimen: 30/15 mg QD; but not approved for stroke prevention). For edoxaban 30/15 mg QD a 41% higher ischaemic stroke risk compared to a well-controlled warfarin arm [median time in therapeutic range (TTR) > 68%] was observed leading to non-approval of this dosing regimen. At the same time, a reduction in haemorrhagic stroke, major bleeding, cardiovascular-, and all-cause mortality was observed compared with warfarin. This was confirmed in a recent direct comparison of the lower-dose edoxaban regimen (30 mg/15 mg) and higher-dose edoxaban regimen (60 mg/
Table 4  Absorption and metabolism of the different NOACs

<table>
<thead>
<tr>
<th></th>
<th>Dabigatran 106,376</th>
<th>Apixaban 517</th>
<th>Edoxaban 518</th>
<th>Rivaroxaban 519,520</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioavailability</td>
<td>3–7%</td>
<td>50%</td>
<td>62%</td>
<td>15 mg/20 mg: 66% without food, 100% with food</td>
</tr>
<tr>
<td>Prodrug</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Clearance non-renal/renal of absorbed dose</td>
<td>20%/80%</td>
<td>73%/27%</td>
<td>50%/50%</td>
<td>No</td>
</tr>
<tr>
<td>Plasma protein binding</td>
<td>35%</td>
<td>87%</td>
<td>55%</td>
<td>95%</td>
</tr>
<tr>
<td>Dialysability</td>
<td>50–60% (In part dialysable)</td>
<td>14%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Glucoronic acid conjugation</td>
<td>CYP3A4 (25%), CYP1A2, CYP2J2, CYP2C8, CYP2C9, CYP2C19</td>
<td>CYP3A4 (&lt;4% of elimination)</td>
<td>CYP2A4 (18%)&lt;sup&gt;a&lt;/sup&gt;, CYP2J2</td>
</tr>
<tr>
<td>Absorption with food</td>
<td>No effect</td>
<td>No effect</td>
<td>6–22% more; minimal effect on exposure</td>
<td>+39% more (see above)</td>
</tr>
<tr>
<td>Absorption with H2B/PPI</td>
<td>–12% to 30% (not clinically relevant)</td>
<td>No effect</td>
<td>No effect</td>
<td>No effect</td>
</tr>
<tr>
<td>Time to peak levels (h)</td>
<td>3</td>
<td>3</td>
<td>2–4</td>
<td>2–4</td>
</tr>
<tr>
<td>Elimination half-life (h)</td>
<td>12–17</td>
<td>12</td>
<td>10–14</td>
<td>5–9 (young) 11–13 h (elderly)</td>
</tr>
</tbody>
</table>

NOAC, non-vitamin K antagonist oral anticoagulant.

Figure 5  Absorption and metabolism of the different NOACs. There are interaction possibilities at the level of absorption or first transformation, and at the level of metabolization and excretion. *Also via CYP1A2, CYP2J2, CYP2C8, CYP2C9, and CYP2C19. NOAC, non-vitamin K antagonist oral anticoagulant.
30 mg).\textsuperscript{100} For dabigatran 110 mg BID, a similar stroke risk and significantly reduced major bleeding vs. warfarin was observed.\textsuperscript{48} These data represent the only available RCT-based evidence of a ‘lower dose’ of a NOAC for stroke prevention in AF on hard clinical endpoints.\textsuperscript{48,49} In contrast, no ‘lower dose’ arm was included (only ‘dose reduction’) in ROCKET-AF (for rivaroxaban) or ARISTOTLE (for apixaban) and as such, no clinical outcome data are available for the use of these reduced doses outside the tested dose reduction algorithms. The ‘Japanese ROCKET’ (J-ROCKET) study demonstrated a safety profile of 15 mg QD rivaroxaban as standard dose for stroke prevention in AF in Japanese patients as compared to VKA but was not powered for efficacy outcomes.\textsuperscript{101} In the ELDERCARE-AF trial, Japanese patients >80 years of age deemed unsuitable for anticoagulation receiving a very low and unapproved dose of 15 mg QD edoxaban showed a 4.4%/year absolute risk reduction in stroke/systemic embolism as compared to placebo, at the cost of a non-significant 1.5%/year absolute increase in the risk of major bleeding.\textsuperscript{102} Whether these findings translate to non-Japanese populations remains to be determined.

The use of plasma level measurements for NOAC dose-adjustment or in the setting of ‘off label’ lower dose prescription (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section) is discouraged for the vast majority of patients due to the lack of outcome data to support such an approach. Indeed, an increased risk of bleeding frequently goes along with an increased risk of stroke due to the overlapping risk factors (including advanced age, frailty etc.), and inappropriate use of a reduced dose may result in sub-optimal stroke prevention.\textsuperscript{103} However, in rare cases of potentially substantial DDIs or special situations in which a certain NOAC is preferred for certain reasons (e.g. patients after transplantation, patients on HIV medication etc.) this may be considered (Figure 6).\textsuperscript{104}

Importantly, this approach should be limited to centres with extensive experience in the performance and interpretation of such assays as well as in the care of NOAC-treated patients (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section). In summary, possible DDIs, especially when combined with other clinical risk factors affecting NOAC plasma levels are important aspects for choosing a specific NOAC for a specific patient. Table 5 gives an overview of the effect of various frequently used agents on NOAC plasma levels; Table 6 focuses on common cancer drugs (see also ‘NOACs in patients with atrial fibrillation and malignancy’ section), Table 7 on antiepileptic drugs (AEDs) (see also ‘NOACs in other special populations’ section) and Table 8 on common herbal products. There are several major limitations particularly regarding

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure6.png}
\caption{NOAC selection based on drug–drug interactions and/or risk of bleeding. Dose reduction of all NOACs is primarily recommended along the published dose reduction criteria (see ‘NOAC eligibility and dosing’ section, Table 2). Whenever possible, the tested and approved dosing regimen of NOACs should be used. See text for details. Use of plasma level measurements to guide dosing is generally discouraged and should only be used in rare cases of potentially substantial interactions or special situations, and only in centers with great experience in the performance and interpretation of such assays as well as the care of NOAC-treated patients (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section). BID, twice daily; NOAC, non-vitamin K antagonist oral anticoagulant; PK, pharmacokinetic; RCT, randomized clinical trial; VKA, vitamin K antagonist.}
\end{figure}
# Table 5: Effect of drug-drug interactions and clinical factors on NOAC plasma levels and anticoagulant effects

<table>
<thead>
<tr>
<th></th>
<th>Via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P-gp substrate</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>
| **CYP3A4 substrate**     | No                       | Yes (=25%) | No (<4%) | Yes (=18%)

## Antiarrhythmic drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>P-gp Inhibition</th>
<th>No PK data</th>
<th>CYP3A4 Inhibition</th>
<th>+12% to 60%&lt;sup&gt;a&lt;/sup&gt;</th>
<th>+40%&lt;sup&gt;a,b&lt;/sup&gt;</th>
<th>Minor effect&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone</td>
<td>Moderate P-gp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>P-gp competition</td>
<td></td>
<td>No effect&lt;sup&gt;a&lt;/sup&gt;</td>
<td>+12% to 60%&lt;sup&gt;a&lt;/sup&gt;</td>
<td>No effect&lt;sup&gt;a&lt;/sup&gt;</td>
<td>No effect&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diltiazem</td>
<td>Weak P-gp and</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dronedarone</td>
<td>P-gp and CYP3A4</td>
<td>+70% to 100%</td>
<td></td>
<td>+85%&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td>Moderate effect; should be avoided</td>
</tr>
<tr>
<td>Quinidine</td>
<td>P-gp inhibition</td>
<td>+53%&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td>+77%&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Extent of increase unknown</td>
</tr>
<tr>
<td>Verapamil</td>
<td>P-gp inhibition and weak CYP3A4 inhibition</td>
<td>+12% to 180%&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td>+53%&lt;sup&gt;a&lt;/sup&gt;</td>
<td>+40%&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Moderate effect; should be avoided</td>
</tr>
</tbody>
</table>

## Other cardiovascular drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>P-gp Inhibition</th>
<th>No relevant interaction&lt;sup&gt;a&lt;/sup&gt;</th>
<th>No data yet</th>
<th>No effect&lt;sup&gt;a&lt;/sup&gt;</th>
<th>No effect&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ticagrelor (see also ‘Patients with atrial fibrillation and coronary artery disease’ section)</td>
<td>P-gp inhibition</td>
<td>+24% to 65%&lt;sup&gt;a&lt;/sup&gt;</td>
<td>No data – carefully monitor</td>
<td>No data – carefully monitor</td>
<td>No data – carefully monitor</td>
</tr>
</tbody>
</table>

## Antibiotics

<table>
<thead>
<tr>
<th>Drug</th>
<th>P-gp Inhibition and strong CYP3A4 inhibition</th>
<th>Clarithromycin: +19% AUC; +15% C&lt;sub&gt;max&lt;/sub&gt; (SmPC)</th>
<th>Clarithromycin: +60% AUC; +30% C&lt;sub&gt;max&lt;/sub&gt; (SmPC)</th>
<th>Erythromycin: +85% AUC; +68% C&lt;sub&gt;max&lt;/sub&gt; (dose reduction to 30 mg once daily by label)</th>
<th>Clarithromycin: +50% AUC; +40% C&lt;sub&gt;max&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rifampicin</td>
<td>P-gp, BCRP and CYP3A4 induction</td>
<td>− 66% AUC; − 67% C&lt;sub&gt;max&lt;/sub&gt; (SmPC)</td>
<td>− 54% AUC; − 42% C&lt;sub&gt;max&lt;/sub&gt; (SmPC)</td>
<td>− 35% AUC; (but with compensatory increase of active metabolites)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>− 50% AUC; − 22% C&lt;sub&gt;max&lt;/sub&gt;</td>
</tr>
</tbody>
</table>

Continued
### Antiviral Drugs

<table>
<thead>
<tr>
<th></th>
<th>via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV protease inhibitors (e.g., ritonavir)</td>
<td>P-gp and BCRP inhibition or induction; CYP3A4 inhibition</td>
<td>Variable increase / decrease</td>
<td>Strong increase</td>
<td>No data yet</td>
</tr>
</tbody>
</table>

### Fungostatics

<table>
<thead>
<tr>
<th></th>
<th>via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluconazole</td>
<td>Moderate CYP3A4 inhibition</td>
<td>No data yet</td>
<td>No data yet</td>
<td>No data yet</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Potent P-gp and BCRP competition; strong CYP3A4 inhibition</td>
<td>+140 to 150% (itraconazole) (US: 1 – 75 mg if CrCl 30-50 mL/min)</td>
<td>+140% AUC; +64% Cmax (itraconazole)</td>
<td>+160% AUC; +72% Cmax (itraconazole, SmPC)</td>
</tr>
</tbody>
</table>

### Other drugs

<table>
<thead>
<tr>
<th></th>
<th>via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voriconazole</td>
<td>Strong CYP3A4 inhibition</td>
<td>No data yet</td>
<td>SmPC</td>
<td>SmPC</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>Mild to moderate P-gp inhibition, strong CYP3A4 inhibition</td>
<td>SmPC</td>
<td>SmPC</td>
<td>SmPC</td>
</tr>
</tbody>
</table>

### Other factors

<table>
<thead>
<tr>
<th></th>
<th>via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥ 80 years</td>
<td>Potential for increased plasma levels</td>
<td>110mg BID (SmPC)</td>
<td>b</td>
<td>c</td>
</tr>
<tr>
<td>Age ≥ 75 years</td>
<td>Potential for increased plasma levels</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight ≤ 60 kg (see ‘NOACs in high- and low body weights’ section)</td>
<td>Potential for increased plasma levels</td>
<td></td>
<td>b</td>
<td>(dose reduction to 30mg according to label)</td>
</tr>
<tr>
<td>Weight ≥ 120 kg (see ‘NOACs in high- and low body weights’ section)</td>
<td>Potential for decreased plasma levels</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>Potential for increased plasma levels</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other factors with potentially increased bleeding risk</td>
<td>For example: Concomitant antplatelet drugs; NSAID; systemic steroid therapy; other anticoagulants Severe Frueity / falls risk History of bleeding or predisposition (anemia, thrombocytopenia)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Colour coding is based on the respective NOAC SmPC, drug interaction databases, or expert opinion. The hatched colour coding indicates no clinical or PK data available. Some of the colour codes will likely require adaptation as more data become available over time.

**White**: No relevant drug–drug interaction anticipated.

**Yellow**: Caution required, especially in case of polypharmacy or in the presence of ≥2 yellow/bleeding risk factors (see Figure 6).

**Orange**: Lower dose (dabigatran) or dose reduction (edoxaban) recommended according to label.

**Red**: Contraindicated/not advisable due to increased plasma levels.

**Blue (dark)**: Contraindicated due to reduced NOAC plasma levels.

**Blue (light)**: Caution required, especially in case of polypharmacy or in the presence of ≥2 light blue interactions due to reduced NOAC plasma levels.

**AUC**: area under the curve; BCRP, breast cancer resistance protein; BID, twice daily; CrCl, creatinine clearance; NOAC, non-vitamin K antagonist oral anticoagulant; NSAID, non-steroidal anti-inflammatory drug; PK, pharmacokinetic; PPI, proton pump inhibitor.

*Based on in vitro investigations, comparing the IC50 for P-gp inhibition to maximal plasma levels at therapeutic dose, and/or on interaction analysis of efficacy and safety endpoints in the Phase-3 clinical trials. No direct PK interaction data available.

*Based on published criteria (see Table 2).

*Age had no significant effect after adjusting for weight and renal function.

*Data from Phase I study. Interpret in the light of data from Re-DUAL PCI (see ‘Patients with atrial fibrillation and coronary artery disease’ section for details).
### Table 6  Anticipated effects of common anti-cancer drugs on non-vitamin K antagonist oral anticoagulants plasma levels

<table>
<thead>
<tr>
<th>Drug</th>
<th>Via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-gp substrate</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>CYP3A4 substrate</td>
<td>No</td>
<td>≈25%</td>
<td>&lt;4%</td>
<td>≈18%</td>
</tr>
</tbody>
</table>

### Antimitotic agents

<table>
<thead>
<tr>
<th>Drug</th>
<th>Efficacy</th>
<th>Via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paclitaxel</td>
<td>Moderate CYP3A4 induction; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinblastine</td>
<td>Strong P-gp induction; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Docetaxel, Vincristine</td>
<td>Mild CYP3A4 induction; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinorelbine</td>
<td>CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Antimetabolites

<table>
<thead>
<tr>
<th>Drug</th>
<th>Efficacy</th>
<th>Via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methotrexate</td>
<td>P-gp competition; no relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pemetrexed, Purine analogues, Pyrimidine analogues</td>
<td>No relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Topoisomerase inhibitors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Efficacy</th>
<th>Via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topotecan</td>
<td>No relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irinotecan</td>
<td>CYP3A4/P-gp competition; No relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>Mild CYP3A4 inhibition; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Anthracyclines / Anthracenediones

<table>
<thead>
<tr>
<th>Drug</th>
<th>Efficacy</th>
<th>Via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin</td>
<td>Strong P-gp induction, mild CYP3A4 inhibition; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Idarubicin</td>
<td>Mild CYP3A4 inhibition; P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daunorubicin</td>
<td>P-gp competition; No relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitoxantrone</td>
<td>No relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Alkylating agents

<table>
<thead>
<tr>
<th>Drug</th>
<th>Efficacy</th>
<th>Via Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ifosfamide</td>
<td>Mild CYP3A4 inhibition; CYP3A4 competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>Mild CYP3A4 inhibition; CYP3A4 competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lomustine</td>
<td>Mild CYP3A4 inhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Class</td>
<td>Via</td>
<td>Dabigatran etexilate</td>
<td>Apixaban</td>
<td>Edoxaban</td>
<td>Rivaroxaban</td>
</tr>
<tr>
<td>------------</td>
<td>-----</td>
<td>----------------------</td>
<td>----------</td>
<td>----------</td>
<td>-------------</td>
</tr>
<tr>
<td>Busulfan</td>
<td>CYP3A4 competition; no relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendamustine</td>
<td>P-gp competition; no relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorambucil, Melphalan, Carmustine, Procarbazine, Dacarbazine, Temozolomide</td>
<td>no relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Platinum-based agents**

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Via</th>
<th>Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin, Carboplatin, Oxaliplatin</td>
<td>No relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Intercalating agents**

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Via</th>
<th>Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bleomycin, Dactinomycin</td>
<td>No relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitomycin C</td>
<td>P-gp competition; no relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Tyrosine kinase inhibitors**

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Via</th>
<th>Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imatinib, Crizotinib</td>
<td>Strong P-gp inhibition, moderate CYP3A4 inhibition; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nilotinib, Lapatinib</td>
<td>Moderate-to-strong P-gp inhibition, mild CYP3A4 inhibition; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venurafenib</td>
<td>Moderate CYP3A4 induction; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dasatinib</td>
<td>Mild CYP3A4 inhibition; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vandetanib, Sunitinib</td>
<td>Strong P-gp inhibition; CYP3A4 competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erlotinib, Gefitinib</td>
<td>CYP3A4 competition; no relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Monoclonal antibodies**

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Via</th>
<th>Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brentuximab</td>
<td>CYP3A4 competition; no relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rituximab, Alemtuzumab, Cetuximab, Trastuzumab, Bevacizumab</td>
<td>No relevant interaction assumed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Continued**
### Hormonal agents

<table>
<thead>
<tr>
<th></th>
<th>Via</th>
<th>Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abiraterone</td>
<td>Moderate CYP3A4 inhibition, strong P-gp inhibition; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enzalutamide</td>
<td>Strong CYP3A4 induction, strong P-gp inhibition; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bicalutamide</td>
<td>Moderate CYP3A4 inhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>Strong P-gp inhibition, mild CYP3A4 inhibition; CYP3A4 competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anastrozole</td>
<td>Mild CYP3A4 inhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flutamide</td>
<td>CYP3A4 competition; no relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Letrozole, Fulvestrant</td>
<td>CYP3A4 competition; no relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raloxifene, Leuprolide, Mitotane</td>
<td>No relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Immune-modulating agents

<table>
<thead>
<tr>
<th></th>
<th>Via</th>
<th>Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciclosporine</td>
<td>Strong-to-moderate P-gp inhibition, moderate CYP3A4 inhibition; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td>+73% AUC (dose reduction to 30 mg once daily by label)</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>Moderate CYP3A4 induction; CYP3A4 competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>Strong-to-moderate P-gp inhibition, mild CYP3A4 inhibition; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisone</td>
<td>Moderate CYP3A4 induction; CYP3A4 competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temsirolimus, Sirolimus</td>
<td>Mild CYP3A4 inhibition; CYP3A4/P-gp competition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Everolimus</td>
<td>CYP3A4 competition; no relevant interaction anticipated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Colour coding is based on the respective NOAC SmPC, drug interaction databases, or expert opinion. The hatched colour coding indicates no clinical or PK data available. Some of the colour codes will likely require adaptation as more data become available over time.

- White: No relevant drug–drug interaction anticipated.
- Yellow: Caution required, especially in case of polypharmacy or in the presence of ≥2 yellow/bleeding risk factors (see Figure 6).
- Orange: Consider avoiding concomitant use, careful monitoring required if combined. See Figure 6.
- Blue (dark): Contraindicated/not advisable due to increased plasma levels.
- Blue (light): Caution required, especially in case of polypharmacy or in the presence of ≥2 light blue interactions due to reduced NOAC plasma levels.
- Where no data or SmPC instructions were available, expert opinion was generally based on the following principles:
  - Strong CYP3A4 and/or P-gp inducer—should not be used (dark blue).
  - Moderate CYP3A4 or P-gp inducer—use with caution or avoid (light blue).
  - Strong CYP3A4 and/or inhibitor—should not be used (red).
  - Moderate CYP3A4 and/or P-gp inhibitor—use with caution or avoid (orange).
  - Mild CYP3A4 and/or P-gp inducers or inhibitors—caution required especially with polypharmacy or in the presence of ≥2 bleeding risk factors (yellow).

Purine analogues: Mercaptopurine, Thioguanine, Pentostatin, Cladribine, Clofarabine, Fluorarabine.
Pirimidine analogues: Fluorouracil, Capecitabine, Cytarabine, Gemcitabine, Azacitadine, Decitabine.
the assessment of NOACs—herbal drug interactions including the possibility of several hypothetical pharmacokinetic and pharmacodynamic pathways, unknown mechanisms of interaction, and the inherent variation in composition. As such, firm advice regarding the safety of use is difficult to give. Particularly in patients with additional risk factors, plasma level measurements may be considered (including its inherent limitations, as discussed above).

Taking into consideration these factors as well as the setup and results from the large randomized NOAC outcome trials the algorithm shown in Figure 6 may assist in a rational selection of a specific NOAC and/or a ‘reduced dose’ based on DDIs and other clinical risk factors. Unfortunately, for many potential interactions with drugs that are often used in AF patients no detailed information is available yet (hatched in Tables 5–9).

### Table 7  Anticipated effects of common antiepileptic drugs on non-vitamin K antagonist oral anticoagulants plasma levels

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P-gp substrate</strong></td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>CYP3A4 substrate</strong></td>
<td>No</td>
<td>Yes (=25%)</td>
<td>No (&lt;4%)</td>
<td>Yes (=18%)</td>
</tr>
</tbody>
</table>

**Drug**

- *Brivaracetam* – No relevant interaction known/assumed
- *Carbamazepine* Strong CYP3A4/P-gp induction; CYP3A4 competition -29% 
- *Ethosuximide* CYP3A4 competition
- *Gabapentin* – No relevant interaction known/assumed
- *Lacosamide* – No relevant interaction known/assumed
- *Lamotrigine* P-gp competition
- *Levetiracetam* P-gp induction; P-gp competition
- *Oxcarbazepine* CYP3A4 induction; P-gp competition
- *Phenobarbital* Strong CYP3A4/possible P-gp induction
- *Phenytoin* Strong CYP3A4/P-gp induction; P-gp competition
- *Pregabalin* – No relevant interaction known/assumed
- *Topiramate* CYP3A4 induction; CYP3A4 competition
- *Valproic acid* CYP3A4/P-gp induction/inhibition
- *Zonisamide* CYP3A4 competition; weak P-gp inhibition

*Colour coding is based on the respective NOAC SmPC, drug interaction databases, or expert opinion.*

- The hatched colour coding indicates no clinical or PK data available.
- Some of the colour codes will likely require adaptation as more data become available over time.
- **White:** No relevant drug–drug interaction anticipated.
- **Blue (dark):** Contraindicated due to reduced NOAC plasma levels.
- **Blue (light):** Caution required, especially in case of polypharmacy or in the presence of ≥2 light blue interactions due to reduced NOAC plasma levels.
Food intake, antacids, and nasogastric tube administration

Rivaroxaban for stroke prevention in AF (20 mg/15 mg QD) needs to be taken with food since the area under the curve (AUC) of the plasma concentration increases by 39% to a very high bioavailability of almost 100%. There is no relevant food interaction with the other NOACs. The concomitant use of PPIs and H₂-blockers leads to a reduction in the bioavailability of dabigatran, but without effect on clinical efficacy. There is also no relevant antacid interaction for the other NOACs. There are no pharmacokinetic data on fish oil supplements for any of the NOACs, but interaction is unlikely. Data have shown that administration in crushed form, e.g. via a nasogastric tube, does not alter the bioavailability for apixaban, rivaroxaban, and edoxaban.

### Table 8  Anticipated effects of common herbal medicines on non-vitamin K antagonist oral anticoagulants plasma levels

<table>
<thead>
<tr>
<th>Drug</th>
<th>Via</th>
<th>Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-gp substrate</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>CYP3A4 substrate</td>
<td>No</td>
<td>Yes (=25%)</td>
<td>No (&lt;4%)</td>
<td>Yes (=18%)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Via</th>
<th>Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curcumin</td>
<td>P-gp inhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Echinacea purpurea</td>
<td>Mild CYP3A4 inhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garlic</td>
<td>Mild CYP3A4 inhibition; anticoagulation / antiplatelet effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ginger</td>
<td>Anticoagulation / antiplatelet effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ginkgo biloba</td>
<td>P-gp inhibition; anticoagulation / antiplatelet effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ginseng</td>
<td>Anticoagulation / antiplatelet effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Green Tea</td>
<td>P-gp inhibition; anticoagulation / antiplatelet effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Horse chestnut</td>
<td>Anticoagulation / antiplatelet effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>St. John’s wort</td>
<td>P-gp/ BCRP and CYP3A4 induction</td>
<td>Should be avoided (per SmPc)</td>
<td>“With caution” (per SmPc)</td>
<td>“With caution” (per SmPc)</td>
<td>Should be avoided (per SmPc)</td>
</tr>
<tr>
<td>Valerian</td>
<td>Mild CYP3A4 inhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Colour coding is based on the respective NOAC SmPC, drug interaction databases, or expert opinion. The hatched colour coding indicates no clinical or PK data available. Some of the colour codes will likely require adaptation as more data become available over time.

Major limitations regarding the assessment of NOACs—herbal drug interactions include the possibility of several hypothetical pharmacokinetic and pharmacodynamic pathways, unknown mechanisms of interaction, and the inherent variation in composition.

Yellow: Caution required, especially in case of polypharmacy or in the presence of ≥2 yellow/bleeding risk factors (see Figure 6).

Blue (dark): Contraindicated/not advisable due to reduced NOAC plasma levels.

Where no data or SmPC instructions were available, expert opinion was generally based on the following principles:

- Strong CYP3A4 and/or P-gp inducer—should not be used (dark blue).
- Mild CYP3A4 and/or P-gp inducers or inhibitors or pharmacodynamic interaction—caution is needed especially with polypharmacy or in the presence of ≥2 bleeding risk factors (yellow).
Interactions of specific drug classes and considerations for polypharmacy are discussed in the Supplementary material online.

**Pharmacodynamic interactions**

Apart from the pharmacokinetic interactions, co-administration of NOACs with other anticoagulants, platelet inhibitors (e.g. aspirin, clopidogrel, ticlopidine, prasugrel, ticagrelor; see also ‘Patients with atrial fibrillation and coronary artery disease’ section), and NSAIDs increases the risk of bleeding. Therefore, such combinations should be carefully balanced against the potential benefit in each clinical situation. Co-administration of NOACs with dual antiplatelet drugs requires active measures to prevent bleeding (see ‘Patients with atrial fibrillation and coronary artery disease’ section).

**NOACs in patients with chronic kidney disease or advanced liver disease**

**Atrial fibrillation and chronic kidney disease**

AF and chronic kidney disease (CKD) are not only frequent comorbidities but also strongly interacting diseases: AF facilitates the development and progression of CKD, and, vice versa, the prevalence and incidence of AF increase with decreasing renal function. Patients with AF and CKD have a markedly increased morbidity and mortality especially due to their excessive risk for both thromboembolic and severe bleeding events, making risk stratification and treatment challenging. This is of particular relevance since all four available NOACs are in part eliminated by the kidneys: dabigatran has the greatest extent of renal elimination (80%), while 50%, 35%, and 27% of edoxaban, rivaroxaban, and apixaban, respectively, are cleared via the kidneys.

Further details regarding the available data on NOACs in patients with CKD are discussed in detail in the Supplementary material online. Basic information on the diagnosis/staging of CKD and assessment of renal function is provided in Table 10. Practical considerations for the use of NOACs based on renal function are summarized in Figure 7.

**Oral anticoagulant therapy in patients with severe CKD (CrCl of 15–29 mL/min)**

There are no RCT data on the use of warfarin for thromboprophylaxis in AF patients with severe CKD or on dialysis, and all landmark trials with NOACs essentially excluded patients with a creatinine clearance (CrCl) of <30 mL/min (apart from few patients on apixaban with CrCl 25–30 mL/min). In the US (but not in Europe), a low dose dabigatran 75 mg BID has been approved for patients with severe CKD (a CrCl of 15–29 mL/min), based on pharmacokinetic simulations. Rivaroxaban, apixaban, and edoxaban (but not dabigatran) are approved in Europe for the use in patients with severe CKD (stage 4, i.e. a CrCl of 15–29 mL/min), with a reduced dose regimen (Figure 7). Observational data indicate a favourable efficacy and safety profile of all three FXa inhibitors compared to VKA in patients with severe renal dysfunction but these data need to be interpreted with caution based on the inherent high likelihood of substantial residual confounding. The 2020 ESC guidelines recommend the use of factor Xa inhibitors ‘with caution’ and at reduced doses for patients with CrCl 15–29 mL/min.

Apixaban is least renally cleared (27%) and its dose is reduced by 50% under rather stringent conditions; furthermore, the rate of major bleeding with apixaban is reduced more (vs. warfarin) in patients with impaired renal function. Edoxaban is more renally cleared, but its dose reduction to 50% is applied more rapidly and was tested in a large subgroup. Rivaroxaban has an intermediate renal clearance (35%) and is reduced less (by 25%) under similar conditions as edoxaban. In view of the individual NOAC pharmacokinetics (27% renal clearance for apixaban), dose-reduction criteria (50% reduction for apixaban and edoxaban), and available evidence from RCTs, the use of either apixaban or edoxaban may be preferable in these patients, but direct head-to-head comparisons are missing. Given the important limitation of observational studies further randomized RCT-based data are urgently required for these difficult to treat patients.

**Oral anticoagulant therapy in patients with end-stage CKD (CrCl of 15 mL/min and/or dialysis)**

Numerous observational studies have reported conflicting results for the use of both VKA and NOACs in patients with end-stage renal disease regarding effectiveness and bleeding without a clear signal for a benefit of OAC. A propensity score matched analysis of 4,537 Medicare patients as well as a meta-analysis of 16 studies with 71,877 dialysis-dependent patients with AF (about 3000 with NOACs) did not demonstrate a benefit regarding the risk for stroke and thromboembolism but instead found a markedly increased incidence of bleeding complications in patients with OAC compared to those without. The use of VKA in end-stage CKD may in some cases result in calciphylaxis, a painful and often lethal condition caused by calcification and occlusion of cutaneous arteries and arterioles. Moreover, there is also an ongoing controversy about the clinical relevance of aggravated calcifications of the large vessels as well as those of the kidney itself under VKA.

The efficacy and safety of NOACs in patients with end-stage renal dysfunction and on dialysis is unclear and subject to ongoing studies. Plasma levels while on treatment with apixaban 2.5 mg BID as well as with 5 mg, Pokorney et al., presented at ESC 2020), edoxaban 15 mg QD, and rivaroxaban 10 mg QD or 15 mg were found to be similar to patients with the full dose and normal renal function. Initial registry data had indicated a higher incidence of hospitalization or death from bleeding in dialysis-dependent patients with dabigatran or rivaroxaban as compared to VKA. More recent analyses indicated more similar thromboembolic- and bleeding rates with apixaban and rivaroxaban vs. VKA; however, residual confounding is likely to be substantial in these analyses precluding any definitive answer regarding efficacy and safety of NOACs in these patients. Furthermore, two randomized controlled trials have been initiated comparing apixaban vs. VKA ‘RENal Hemodialysis Patients ALlocated Apixaban vs. Warfarin in Atrial Fibrillation’ (RENAL-AF) in the US (NCT02942407), and ‘A Safety Study Assessing Oral Anticoagulation With Apixaban vs. Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment’ (AXADIA) in Germany.
Both studies lacked a third treatment arm without any OAC and both suffered from severe recruitment problems. RENAL-AF has been stopped prematurely after including 154 patients and reported similar rates of major and clinically relevant non-major bleeds as well as a (numerical) doubling of cardiovascular deaths with apixaban vs. warfarin (presented at AHA 2019). Of note, Table 9 Anticipated effects of Medications used in the treatment of Covid-19 on non-vitamin K antagonist oral anticoagulants plasma levels

<table>
<thead>
<tr>
<th>Drug</th>
<th>Via</th>
<th>Dabigatran etexilate</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Rivaroxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-gp substrate</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>CYP3A4 substrate</td>
<td>No</td>
<td>Yes (=25%)</td>
<td>No (&lt;4%)</td>
<td>Yes (=18%)</td>
<td></td>
</tr>
</tbody>
</table>

**Drug**

- **Azithromycin**: P-gp inhibition, No PK data
- **Atazanavir**: CYP3A4 inhibition, No PK data
- **Lopinavir / Ritonavir**: P-gp and BCRP inhibition or induction, CYP3A4 inhibition, No PK data
- **Darunavir / Cobicistat**: CYP3A4 inhibition, P-gp and BCRP inhibition, SmPC
- **Ribavirin**: –
- **Remdesivir**: –
- **Favipiravir**: –
- **Bevacizumab**: –
- **Eculizumab**: –
- **Tocilizumab**: –
- **Fingolimod**: –
- **Interferon**: –
- **Pirfenidone**: –
- **Methylprednisolone**: –
- **Nitazoxanide**: –

Colour coding is based on the respective NOAC SmPC, drug interaction databases, or expert opinion. The hatched colour coding indicates no clinical or PK data available. Some of the colour codes will likely require adaptation as more data become available over time.

White: No relevant drug–drug interaction anticipated.

Yellow: Caution required, especially in case of polypharmacy or in the presence of >2 yellow/bleeding risk factors (see Figure 6).

Orange: Consider avoiding concomitant use, careful monitoring required if combined. See Figure 6.

Red: Contraindicated/not advisable due to increased NOAC plasma levels.

Pink: No information retrievable.

Where no data or SmPC instructions were available, expert opinion was generally based on the following principles:

- Strong CYP3A4 and/or inhibitor—should not be used (red).
- Moderate CYP3A4 and/or P-gp inhibitor—use with caution or avoid (orange).
- Mild CYP3A4 and/or P-gp inducers or inhibitors—caution is needed especially with polypharmacy or in the presence of >2 bleeding risk factors (yellow).

The use of NOACs is not advisable when atazanavir is given in combination with its enhancers ritonavir or cobicistat.
Table 10  Criteria for diagnosing CKD; estimation of renal function and categories of renal dysfunction

<table>
<thead>
<tr>
<th>GFR category</th>
<th>CKD stage</th>
<th>GFR&lt;60 mL/min/1.73 m²</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>1</td>
<td>≥90</td>
<td>Normal or high</td>
</tr>
<tr>
<td>G2</td>
<td>2</td>
<td>60–89</td>
<td>Mildly decreased</td>
</tr>
<tr>
<td>G3a</td>
<td>3</td>
<td>45–59</td>
<td>Mildly to moderately decreased</td>
</tr>
<tr>
<td>G3b</td>
<td>3</td>
<td>30–44</td>
<td>Moderately to severely decreased</td>
</tr>
<tr>
<td>G4</td>
<td>4</td>
<td>15–29</td>
<td>Severely decreased</td>
</tr>
<tr>
<td>G5</td>
<td>5</td>
<td>&lt;15</td>
<td>Kidney failure (requires renal replacement therapy, dialysis or kidney transplantation)</td>
</tr>
</tbody>
</table>

Estimation of renal function in NOAC patients best by Creatinine Clearance (Cockcroft–Gault):

\[
\text{CrCl (mg/dL)} = \frac{\left(140 - \text{age (in years)}\right) \times \text{weight (in kg)} \times (0.85 \text{ if female})}{72 \times \text{serum creatinine (in mg/dL)}}
\]


Popular Apps are NephroCalc, MedMath, MedCalc, Calculate by QxMD, and Archimedes.

Figure 7  Use of NOACs according to renal function. *110 mg BID in patients at high risk of bleeding (per SmPc). **Other dose reduction criteria may apply (weight ≤ 60 kg, concomitant potent P-Gp inhibitor therapy). According to EMA, SmPc edoxaban should be used in ‘high CrCl only after a careful evaluation of the individual thromboembolic and bleeding risk’. See text for details. BID, twice daily; CrCl, creatinine clearance; EMA, European Medicines Agency; NOAC, non-vitamin K antagonist oral anticoagulant; RCT, randomized clinical trial; VKA, vitamin K antagonist.
a large proportion of warfarin patients were outside the therapeutic range (TTR 44%) and about 50% of apixaban patients received 5 mg BID. A third, smaller trial (NCT03987711) comparing warfarin, apixaban, and no anticoagulation is currently ongoing. Despite the lack of data for NOACs (or OAC in general) in dialysis-dependent patients, their usage seems to be increasing.145

In summary, given the lack of strong evidence the decision to anticoagulate and (if so) whether to use a NOAC or VKA in patients with end-stage renal failure or on dialysis requires a high degree of individualization. Measurements of NOAC plasma levels (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section), although intuitively appealing for this situation, has equally never been prospectively investigated for hard clinical endpoints, and should hence be reserved to highly specialized centres. Patients need to be informed of the lack of data as well as the ‘off label’ character of whichever strategy or drug is chosen, including the uncertain benefit and the increased risk of complications. Ideally, such patients should be included in ongoing trials to improve the evidence base for this difficult to treat patient population.121,146

In summary, given the lack of strong evidence the decision to anticoagulate and (if so) whether to use a NOAC or VKA in patients with end-stage renal failure or on dialysis requires a high degree of individualization. Measurements of NOAC plasma levels (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section), although intuitively appealing for this situation, has equally never been prospectively investigated for hard clinical endpoints, and should hence be reserved to highly specialized centres. Patients need to be informed of the lack of data as well as the ‘off label’ character of whichever strategy or drug is chosen, including the uncertain benefit and the increased risk of complications. Ideally, such patients should be included in ongoing trials to improve the evidence base for this difficult to treat patient population.121,146

Of note, there are also no RCT data for the use of alternative stroke prevention strategies such as left atrial appendage (LAA) occluder implantation for these individuals.

There are no data on the use of NOACs in AF patients after kidney transplantation. If NOACs are used in such patients, the dosing regimen should be selected according to the estimated renal function, and caution is needed concerning possible DDIs between the NOAC and concomitant immunosuppressive therapies (see ‘Pharmacokinetics and drug-drug interactions of NOACs’ section).

**NOACs in liver disease**

Practical considerations for the use of NOACs in liver disease are discussed in the Supplementary material online and are summarized in Figure 8.

**NOAC plasma level measurements: technical approach, indications, pitfalls**

**Assessment of the anticoagulant effect of NOACs**

The use of NOAC in daily clinical practice does not require monitoring of coagulation since all four phase III RCTs comparing NOACs to VKAs have been conducted without dose adjustments based on plasma level measurements.46–49 However, assessment of the anticoagulant effect of NOACs may be desirable in certain, rare situations (see below).
NOAC anticoagulant activity can be measured via specific coagulation assays developed for the quantification of NOAC plasma levels. Most routine coagulometers are capable of measuring NOAC plasma levels within ≤30 min. Institutions should strongly consider 24/7 availability of these tests for emergency situations. In contrast, point-of-care tests are being developed and are entering clinical practice, but are not yet widely available.

Anti-FXa chromogenic assays are available to measure plasma concentrations of the FXa inhibitors using validated calibrators. Low and high plasma levels can be measured with acceptable inter-laboratory precision. The absence of anti-Xa activity with these assays excludes clinically relevant drug levels. Conversely, the diluted thrombin time (dTT) test as well as the ecarin chromogenic assay (ECA) display a direct linear relationship with dabigatran concentrations and are suitable for their quantitative assessment. Even though levels in clinical trials were measured using High Performance Liquid Chromatography/Mass Spectrometry (HPLC/MS), drug measurement and monitoring can be closely approximated using a calibrated dTT/ECA assay for dabigatran or chromogenic anti-FXa assay for FXa-inhibitors. These determinations have been demonstrated to be comparable to HPLC/MS.

It is advisable to primarily use FXa-inhibitors. These determinations have been demonstrated to be closely approximated using a calibrated chromogenic anti-FXa assay for dabigatran or chromogenic anti-FXa assay for FXa-inhibitors. These determinations have been demonstrated to be comparable to HPLC/MS.

Consistent with effect on aPTT
Normal values exclude supratherapeutic but not therapeutic levels

Normal values do not exclude trough levels

Normal values do not exclude supratherapeutic levels (if sensitive assay is used)
Normal values do not exclude trough levels (if sensitive assay is used)

Table 11: Plasma levels and coagulation assays in patients treated with NOACs for stroke prevention in AF

<table>
<thead>
<tr>
<th>NOAC</th>
<th>Expected plasma levels of NOACs in patients treated for AF</th>
<th>Expected impact of NOACs on routine coagulation tests</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Peak levels 52–383</td>
<td>PT (1) peak (1) if supratherapeutic</td>
</tr>
<tr>
<td></td>
<td>Trough levels 28–215</td>
<td>aPTT (1) at peak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ACT (1) at peak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TT (1)</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>97,548,549</td>
<td>148,150,158,549,552–554</td>
</tr>
<tr>
<td>Apixaban</td>
<td>550</td>
<td>178–343</td>
</tr>
<tr>
<td>Edoxaban</td>
<td>98,100</td>
<td>12–43</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>519,520,551</td>
<td>12–137</td>
</tr>
</tbody>
</table>

ACT, activated clotting time; AF, atrial fibrillation; aPTT, activated prothrombin time; NOAC, non-vitamin K antagonist oral anticoagulant; PT, prothrombin time.

Impact of NOACs on other coagulation assays
Routine coagulation tests [prothrombin time (PT), activated prothrombin time (aPTT), activated clotting time (ACT)] generally do not provide an accurate assessment of NOAC anticoagulant effects and cannot be used to accurately gauge anticoagulant activity (Table 11) or provide information on adherence to treatment. However, a normal aPTT excludes supratherapeutic levels in dabigatran-treated patients. The effect of apixaban, edoxaban, and rivaroxaban on the PT is highly dependent on the PT reagent used. Therefore, a normal PT does not necessarily exclude therapeutic levels of rivaroxaban, edoxaban, and particularly apixaban.

Point-of-care INR devices developed to monitor VKAs do not accurately reflect the anticoagulant status of NOAC treated patients.

There is not enough information to consider the use of thromboelastography or rotational thromboelastometry for adequately assessing NOAC activity, as they lose sensitivity at trough levels of the NOACs. Urine tests may be useful for detecting exposure to NOACs but levels do not correlate well with plasma concentrations.

Impact of NOACs on thrombophilia testing
NOACs interfere with thrombophilia tests and the measurement of coagulation factors. Therefore, leaving a time window of at least 24 h is reasonable between the last intake of a NOAC and blood sampling to confidently assess coagulation parameters. This time window may need to be even longer for lupus
anticoagulant measurements (≥48 h) or in the presence of factors potentially prolonging the anticoagulant effect such as CKD. In patients in whom interruption of anticoagulation is not feasible, ex vivo neutralization of the NOAC activity in plasma samples is possible in specialized haemostasis labs. This may allow for correct interpretation of thrombophilia tests, but requires good collaboration with the haemostasis lab and appropriate clinical information.160,161

Potential indications for NOAC plasma level measurements
No studies have investigated if measurement of drug levels and dose adjustment based on laboratory coagulation parameters, e.g. by dose reduction in case of higher than expected levels or by dose increase in case of lower than expected levels, improve the overall benefit of NOACs during long-term treatment. As such, routine monitoring of plasma levels and subsequent dose adaptation is generally discouraged.

However, laboratory assessment of drug exposure and anticoagulant effect may help clinicians in emergencies such as bleeding (see ‘Management of bleeding under NOAC therapy’ section), suspected overdose, and acute stroke (see ‘AF patients presenting with acute stroke while on NOACs’ section). Also, in special situations during long-term care such as multiple possible DDIs (see ‘Pharmacokinetics and drug-drug interactions of NOACs’ section), extremes of bodyweight (see ‘NOACs in high- and low body weights’ section), or severely impaired renal function (see ‘NOACs in patients with chronic kidney disease or advanced liver disease section’) plasma level measurements may aid in the clinical decision-making. This, however, should only be done under the guidance of a coagulation expert and in the knowledge that prospective randomized clinical outcome data still do not exist to support such a strategy (only observational data).104,162–164 Also patients need to be informed of and consent to this ‘off-label’ approach.

Management of bleeding under NOAC therapy

General aspects
The phase III trials have consistently shown that NOACs cause less intracranial and less life-threatening bleeds than warfarin, despite the
absence of specific reversal agents in these trials. Not only was there a similar or even a reduced bleeding incidence, but patients experiencing a major (particularly extracranial) bleed under NOACs were also shown to have a more favourable outcome than for bleeding under VKA treatment.165–169 This is underlined by the reduction in all-cause mortality as well as life-threatening/fatal bleeds which was observed with NOACs vs. warfarin.6,46,49,165,170

Nevertheless, as more patients are being treated with NOACs, the absolute number of NOAC-related bleeding events increases. Importantly, any bleed is an opportunity to review the correct choice and dosing of the NOAC (see ‘NOAC eligibility and dosing’ section) and to evaluate modifiable bleeding risk factors including sub-optimally treated hypertension, excessive alcohol intake and concomitant antiplatelet therapy, NSAIDs, glucocorticoids etc.1

To optimally manage NOAC-treated patients who present with a bleed we strongly suggest developing a hospital-wide policy in an interdisciplinary manner among cardiologists, haemostasis experts, emergency physicians/intensive care specialists, surgeons, and others. This protocol should describe the availability, timing, and indications of specific coagulation tests as well as the availability and use of specific and nonspecific reversal agents. Such a policy needs to be communicated well and be easily accessible (e.g. on an intranet site, in the emergency room, in pocket-sized leaflets etc.). In addition, a regular interdisciplinary review and discussion of patients experiencing severe bleeding complications (as well as strokes) is encouraged in order to share different subspecialty experiences as well as patient perception of such events and subsequent preferences.

Strategies to manage bleeding complications in patients treated with NOACs rely on a precise analysis of the clinical situation (Figure 9).

(1) The type of bleeding: nuisance/minor, major non-life threatening, or life-threatening.

– Based on clinical judgement—including location, extents, patient’s age, comorbidities, ...

– Potentially supported by ‘official’ bleeding definitions [e.g. TIMI,171 International Society of Thrombosis and Hemostasis (ISTH),172 GUSTO,173 or others]

(2) The patient and his/her treatment, including:

– The exact time of last NOAC intake

– Prescribed dosing regimen

– Renal function

– Other factors influencing plasma concentrations (e.g. hepatic function, co-medications etc.)

– Other factors influencing haemostasis (e.g. concomitant use of antiplatelet drugs).

(3) The patient’s thromboembolic risk

– Particularly when considering the use of prothrombotic agents, and regarding the necessity of (early) re-initiation of anticoagulant therapy

Both routine coagulation tests and assays that specifically measure NOAC plasma levels are important adjuncts in the assessment of NOAC related bleeds (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section).174 Normal results of dTT/ecarin clotting time (for dabigatran) or anti-Xa activity (for anti-FXa treated patients) exclude relevant levels of the respective anticoagulants. Importantly, conventional coagulation tests may be

---

**Figure 10** Application and effect of idarucizumab and andexanet alpha. Per Andexanet Alpha SmPC.496 *Or unknown. Andexanet alpha is currently only approved for reversal of life-threatening uncontrollable bleeding in patients taking apixaban or rivaroxaban. In view of the very similar mode of action and preliminary subanalyses from the ANNEXA-4 trial (Benz et al., presented at at the International Stroke Conference meeting 2021), it can be assumed that it will have a similar effect in patients on edoxaban. The edoxaban dosing provided in this scheme is based on the (final) protocol of the ANNEXA-4 trial.185 dTT, diluted thrombin time.
abnormal not only due to the effect of the NOAC itself, but for a variety of other reasons, particularly in the setting of severe bleeding and consumption coagulopathy. Conversely, it needs to be kept in mind that restoration of coagulation alone does not necessarily result in improved clinical outcome (e.g. in the context of intracranial hemorrhage).175,176

Practical advice for the management of nuisance/minor bleeding and non-life-threatening major bleeding is summarized in Figure 9 and discussed in the Supplementary material online.

Life-threatening bleeding or bleeding into a critical site

Patients with a life threatening bleed or bleeding into a critical site172,174,177,178 while treated with NOACs may benefit from its reversal in addition to the standard measures outlined above and in Figure 9. Although laboratory values (including a full coagulation panel) should be taken prior to any reversal measures in order to guide further treatment during the course, immediate actions are guided by clinical assessment without waiting for the results of laboratory measurements. Conversely and importantly, normalization of coagulation in itself is not necessarily sufficient to stop a bleed but may allow for more invasive interventions to control the bleeding source. Furthermore, even after direct reversal, significant NOAC concentrations may reappear in some patients and contribute to recurrent or continued bleeding (particularly after andexanet alpha due to its shorter half-life, less after idarucizumab administration),179,180 underlining the necessity for continued clinical and laboratory monitoring.

Idarucizumab

Idarucizumab is a humanized antibody fragment that specifically binds dabigatran. In the ‘Reversal Effects of Idarucizumab in Patients on Active Dabigatran’ (RE-VERSE-AD) study the drug was successfully used in patients on dabigatran presenting with major or life-threatening bleeding, or with the necessity of emergency surgery.181 This was confirmed in the observational REVECTO registry.182 Idarucizumab completely reversed the anticoagulant activity of dabigatran within minutes in almost all patients181 and is hence considered first-line therapy in such situations. A total of 5 g idarucizumab is administered intravenously in two ready-to-use doses of 2.5 g i.v., administered as two consecutive infusions over 5–10 min each or as a bolus injection.183

Continued clinical and laboratory monitoring is strongly advised, since a 5 g dose of idarucizumab may not completely neutralize an exceptionally high level of dabigatran (e.g. in case of overdose or CKD). Also, low levels of dabigatran may reappear after 12–24 h.

After 24 h, dabigatran can be re-started if clinically indicated and feasible, with normal kinetics. Other anticoagulants, including heparins, are not affected by idarucizumab.

If idarucizumab is not available, dialysis may be used to partially eliminate dabigatran from the circulation.184 However, starting and performing dialysis in a patient with a severe (potentially life-threatening) bleed may be challenging and may only be advisable if idarucizumab is not readily available.

Direct reversal of apixaban, edoxaban, or rivaroxaban (FXa-inhibitors)

Andexanet alfa is a recombinant, inactive human FXa analogue that non-specifically binds FXa inhibitors thereby preventing all FXa inhibitors (including low-molecular weight- and UFHs) from inhibiting FXa. In the ‘Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors’ study (ANNEXA-4) and in the ‘Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXA Inhibitors 4’ study, andexanet alfa was successfully used in major or life-threatening bleeding; in contrast to RE-VERSE-AD, the trial did not include patients undergoing emergency surgery.185 The drug comes as a lyophilized powder which needs to be reconstituted before use. It is administered as a bolus over 15–30 min, followed by a 2-h infusion depending on the NOAC and on the timing since last intake (Figure 10). In the EU Andexanet alfa is only approved for the reversal of life-threatening or uncontrollable bleeding in patients taking apixaban or rivaroxaban. In view of the very similar mode of action and preliminary subanalyses from the ANNEXA-4 trial (Benz et al., presented at the International Stroke Conference meeting 2021) it can be assumed that it will have a similar effect in patients on edoxaban. Since anticoagulant activity may reappear after cessation of the infusion it is currently less clear at what point in time and with which anticoagulant effect FXa inhibitors or heparin can be (re-)administered following andexanet alpha administration.

Coagulation factors

Clinical trials and registry data with NOACs have shown that administration of coagulation factors is rarely needed.186,187 Indeed, any NOAC-antagonizing effect of a procoagulant has to be balanced carefully against the potential prothrombotic effect. Animal experiments as well as studies in healthy volunteers have indicated the potential usefulness of prothrombin complex concentrate (PCC) and activated PCC (aPCC) for the normalization of coagulation parameters under NOAC treatment as a surrogate for haemostatic support.188–194 As indicated above, data from the large phase III trials demonstrated that outcomes of bleeds under NOACs were similar (if not better) than in the VKA arm (with diverse bleeding treatments applied, including PCC/aPCC).165–167 The efficacy on clinical
outcomes of PCCs or aPCCs in patients taking NOACs who are actively bleeding has not been firmly established in an RCT. However, several observational studies in patients with major bleedings have been published (with some inherent limitations including the retrospective, non-controlled setting as well as absence of a control group) indicating that (a)PCCs appeared to be efficacious in supporting haemostasis.195–199 It usefulness in intracranial Haemorrhage, on the other hand, is uncertain (see ‘AF patients presenting with acute stroke while on NOACs’ section).200 The administration of PCCs or aPCCs can hence be considered in a patient with a life-threatening bleed if immediate haemostatic support is required, especially in situations where a specific reversal agent is not available or too costly.201 The choice between PCC and aPCC may depend on their availability and the experience of the treatment centre. As indicated, aPCC induces a strong pro-coagulant effect and should only be used by physicians experienced in their use.

PCC and aPCC are preferred over recombinant activated factor VIIa (90 μg/kg) given the absence of any outcome data and the latter’s pronounced pro-coagulant effect.202,203 Fresh frozen plasma (FFP) is no longer considered a useful reversal strategy, primarily due to the plasma abundance of NOACs which will inhibit newly administered coagulation factors upon administration of FFP and the resulting large volume of FFP that would need to be administered to have any impact on coagulation.204 Vitamin K and protamine administration have no role in the management of bleeding under NOACs; these may only be useful in the management of bleeding under NOACs when vitamin K deficiency is suspected or in case of concomitant treatment with heparins, respectively.

(Re-)initiating anticoagulation post-extracranial bleeding
In most cases of nuisance or minor bleeding anticoagulation can be re-started, sometimes simply by delaying or skipping a single dose. All other bleeds, particularly life-threatening bleeding episodes, require a careful re-assessment of the risks and benefits of re-initiating anticoagulation. In most cases of bleeds due to secondary (e.g. bleeding post-trauma) and/or reversible causes (e.g. genito-urinary bleeding due to cancer) anticoagulation can be resumed once the cause of the bleeding has been eliminated. As exemplified for gastro-intestinal bleeds many additional factors need to be taken into consideration (Figure 11). Conversely, for severe and life-threatening bleeds without a clear secondary or reversible/treatable cause, the risks of re-initiating anticoagulation may outweigh the benefits. In such cases, implantation of a LAA occluder or surgical LAA occlusion may be considered as a potential substitute for long-term anticoagulation,5 but RCT-based evidence for LAA occlusion after bleeding under OAC is currently also missing.

The approach after intracranial (intracerebral, subarachnoidal, subdural, or epidural) bleeding is outlined in the section on ‘AF patients presenting with acute stroke while on NOACs’.

Measures to consider in case of a (suspected) overdose without bleeding or a clotting test indicating a potential risk of bleeding
Excessive NOAC plasma concentrations potentially expose the patient to an increased risk of bleeding. This may occur when the patient has (intentionally) taken an overdose, but also intercurrent
### Table 12  Classification of elective surgical interventions according to bleeding risk

<table>
<thead>
<tr>
<th>Minor risk interventions (i.e. infrequent bleeding and with low clinical impact)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dental extractions (1–3 teeth), paradontal surgery, implant positioning, subgingival scaling/cleaning</td>
<td>Cataract or glaucoma intervention</td>
<td>Endoscopy without biopsy or resection</td>
</tr>
<tr>
<td>Superficial surgery (e.g. abscess incision; small dermatologic excisions, skin biopsy)</td>
<td>Electrophysiological study or catheter ablation (except complex procedures)</td>
<td>Routine elective coronary/peripheral artery intervention (except complex procedures)</td>
</tr>
<tr>
<td>Intramuscular injection (e.g. vaccination)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Low-risk interventions (i.e. infrequent bleeding or with non-severe clinical impact)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Complex dental procedures</td>
<td>Endoscopy with simple biopsy</td>
<td>Small orthopaedic surgery (foot, hand, arthroscopy, …)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>High-risk interventions (i.e. frequent bleeding and/or with important clinical impact)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac surgery</td>
<td>Peripheral arterial revascularization surgery (e.g. aortic aneurysm repair, vascular bypass)</td>
<td>Complex invasive cardiological interventions, including lead extraction, (epicardial) VT ablation, chronic total occlusion PCI etc.</td>
</tr>
<tr>
<td>Neurosurgery</td>
<td>Spinal or epidural anaesthesia; lumbar diagnostic puncture</td>
<td>Complex endoscopy (e.g. multiple/large polypectomy, ERCP with sphincterotomy etc.)</td>
</tr>
<tr>
<td>Abdominal surgery (incl. liver biopsy)</td>
<td>Thoracic surgery</td>
<td>Major urologic surgery/biopsy (incl. kidney)</td>
</tr>
<tr>
<td>Major orthopaedic surgery</td>
<td></td>
<td>Extracorporeal shockwave lithotripsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Major orthopaedic surgery</td>
</tr>
</tbody>
</table>

For each patient, individual factors relating to bleeding and thromboembolic risk need to be taken into account and be discussed with the operating physician and the patient (see Figure 13).

---

**Figure 13** Perioperative NOAC management. NOAC, non-vitamin K antagonist oral anticoagulant; NSAID, non-steroidal anti-inflammatory drug.
**Figure 14** Timing of last NOAC intake before an elective intervention. CrCl, creatinine clearance; LMWH, low molecular weight heparin; NOAC, non-vitamin K antagonist oral anticoagulant; UFH, unfractionated heparin.

**Figure 15** Stopping and re-initiation of NOAC therapy in elective surgery. Yellow star—Time point of the intervention/operation. Parentheses indicate optional pre-/postoperative intake, especially in patients not at high risk of drug accumulation/bleeding. Consider ±24 h of interruption in situations likely resulting in increased plasma levels [e.g. body weight < 50 kg, significant interactions (see ‘Pharmacokinetics and drug-drug interactions of NOACs’ section)]. Intake of this dose of dabigatran if CrCl is in the indicated range; otherwise skip this dose. Consider measurement of plasma levels in very special situations, e.g. highest risk neurosurgery/cardiac surgery, severely impaired renal function, combination of factors predisposing to higher NOAC levels (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section). Rivaroxaban needs to be taken with food for stroke prevention in AF, which needs to be considered (also) in the post-operative setting. AF, atrial fibrillation; CrCl, creatinine clearance; NOAC, non-vitamin K antagonist oral anticoagulant.
events such as an acute decline in renal function (especially with dabigatran) or administration of drugs with known DDIs (see ‘Pharmacokinetics and drug–drug interactions of NOACs’ section) may increase NOAC plasma concentrations to supratherapeutic levels. In terms of management, it is important to distinguish between an overdose with resultant bleeding and without. In case of a suspected overdose, assessment of NOAC plasma levels can help determine its degree and possible bleeding risk (Table 11). Given the relatively short plasma half-life of NOACs, a ‘wait-and-see’ strategy can be used in most cases without active bleeding. The elimination half-life can be estimated taking into account age and renal function. As a result of limited absorption, a ceiling effect with little to no further increase in plasma exposure is seen at supra-therapeutic doses of ≥50 mg rivaroxaban.204 There are no data in this respect for the other FXa inhibitors or dabigatran.

In the case of recent acute ingestion of an overdose (especially when ≤2 h ago), the use of activated charcoal to reduce absorption may be considered for any NOAC (with a standard dosing scheme for adults of 30–50 g) although clinical data on its effectiveness are lacking.205,206

If a more aggressive normalization of plasma levels is deemed necessary, or rapid normalization is not expected (e.g. severely impaired renal function) the steps outlined in patients with an active bleed may need to be considered (Figure 9). Only in exceptional cases administration of coagulation factors (PCC, aPCC) awaiting clearance of the drugs should be considered; clearly in these situations balancing the benefit of normalizing coagulation in a non-bleeding patient needs to be carefully weighed against a possibly strong prothrombotic effect.

Patients requiring an urgent surgical intervention

If an emergency intervention is required, any NOAC should be discontinued immediately. Considerations for the specific management depends on the level or urgency (acute emergency, urgent or expedite)207 as summarized in Figure 12 and discussed in the Supplementary material online. In all such situations, particularly prior to the application of any haemostatic agent, a full panel of coagulation assays (including PT, aPTT, anti-FXa, or dTT/ECA etc.) should be obtained to assess the patient’s coagulation status. Even if in an emergency situation the indication for application of reversal- and/or pro-haemostatic agents is governed by the patient’s clinical presentation, results of these initial tests may have important implications for further treatment during the ensuing hours. Furthermore, assessment of NOAC plasma levels may be of great help in interpreting the patient’s anticoagulant status as well as the waning of any NOAC effect (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section).

Patients undergoing a planned invasive procedure, surgery, or ablation

General considerations

About one quarter of anticoagulated patients requires temporary cessation for a planned intervention within 2 years.187 Various societies have issued separate guidelines on the timing of NOAC interruption prior to surgery or interventions. It is impossible to summarize all recommendations, and HCPs are advised to check this guide’s schemes against the relevant recommendations of their country/healthcare setting and professional societies. Ever since its introduction, the EHRA practical guide intended to provide a unified approach which is as simplified as possible to allow for its broad implementation. Data from the PAUSE trial and drug-specific registries have meanwhile added to the evidence that such an approach may be safe and effective across many clinical scenarios, but also that additional individualization based on patient characteristics could further improve safety.208,209

While invasive surgical interventions require temporary discontinuation of NOACs, many less invasive procedures carry a relatively low bleeding risk and may be performed under minimally- or uninter rupted NOAC therapy (Table 12, Figures 13–15). However, patient characteristics (including age, stroke risk, history of bleeding complications, concomitant medication, kidney function etc.) as well as surgical factors need to be taken into account to determine when to discontinue and restart a NOAC (Figure 13). As such, the ‘default’ NOAC interruption periods provided in Figures 14 and 15 may require adaptation based on the individual benefit/risk ratio. It is strongly advisable to develop and implement institutional guidelines and hospital-wide policies concerning perioperative anticoagulation management in different surgical settings, which are widely communicated and readily available. All patients undergoing a planned intervention as well as caregivers (primary care physician etc.) should receive a written note indicating the anticipated date and time of the intervention as well as the date and time of last NOAC intake.

Laboratory testing before surgery or invasive procedures

Specific coagulation measurements (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section) prior to surgery or invasive procedures provide a direct assessment of the residual drug concentration210 and have been proposed in high-risk interventions or interventions in which even some bleeding may have severe consequences. Although theoretically reasonable, HCPs as well as patients need to be aware that adapting the duration of interruption based on residual NOAC levels is without prospectively validated evidence concerning its clinical impact, including the determination of ‘safe’ NOAC levels for different types of procedures. In the ‘Perioperative Anticoagulant Use for Surgery Evaluation’ (PAUSE) trial, patients undergoing low-risk procedures had a higher likelihood of mildly (≥30 ng/mL) or moderately (≥50 ng/mL) elevated NOAC levels due to shorter NOAC interruption times.211 For high-risk procedures, CrCl <50 mL/min, standard (vs. reduced) NOAC dose, body weight <70 kg and female sex were associated with elevated NOAC levels. In the prospective multicentre ‘Concentration of Rivaroxaban, Dabigatran and Apixaban’ (CORIDA) study, CrCl <50 mL/min and use of certain antiarrhythmic drugs (amiodarone, verapamil, diltiazem) were associated with elevated perioperative plasma levels.162 However, elevated NOAC levels were not independently predictive of an increased likelihood of bleeding in either PAUSE or CORIDA.162,211 Hence, although assessment of residual NOAC levels may be considered in certain selected patients, particularly before undergoing high-risk interventions, a ‘time-based’
The interruption schedule as outlined above generally appears safe for the majority of patients and procedures.208,209 Of note, if NOACs are interrupted for >72 h the likelihood of any residual NOAC level appears very low162,211 usually precluding the necessity of NOAC level assessment outside scenarios with very high risk of drug accumulation (e.g. severely reduced renal function).

**Interruption times based on bleeding risk classifications**

Suggested interruptions times based on bleeding risk classifications (Table 12) are discussed in the Supplementary material online and are summarized in Figures 14 and 15.

**Bridging**

Pre-operative bridging with low-molecular weight heparin (LMWH) or UFH is not recommended in NOAC-treated patients since the predictable waning of the anticoagulation effect allows for properly timed short-term cessation of NOAC therapy before surgery. For patients on VKA, bridging with heparin/LMWH was associated with a significantly higher risk of major bleeding during cessation of OAC but did not reduce thromboembolic events.212 Similarly for NOACs, bridging is associated with an increased bleeding risk.187,213–215

Based on prior experience with VKA, the very few very high-risk situations in which bridging may be discussed include urgent surgery with a high bleeding risk in patients with a recent (<3 months) thromboembolic event (including stroke, systemic embolism or venous thrombosis/pulmonary embolism) or who suffered an event during previous adequate interruption of NOAC therapy.216 In these instances, in addition to ‘timed’ NOAC interruption, switching to UFH or low-dose dabigatran—both with the possibility of rapid reversal—around the operation may be evaluated based on a multidisciplinary team decision. Further research on the optimal management in such high-risk patients is required as they were frequently excluded from or under-represented in the available trials addressing perioperative management of NOAC-treated patients.

In patients with chronic coronary artery disease (CAD) treatment with NOAC monotherapy is safe and effective and considered standard therapy for long-term management (see ‘Patients with atrial fibrillation and coronary artery disease’ section).1 However, particularly patients with a high coronary risk may be at risk for perioperative cardiovascular events during NOAC interruption due to the absence of any antithrombotic therapy.217,218 In the ‘Peri-operative Ischaemic Evaluation 2’ (POISE-2) trial, peri-operative aspirin use did not reduce the risk of myocardial infarction (MI) or death but increased the risk of major bleeding in 10 010 patients at risk for vascular complications (one third with a history of vascular disease).219 However, whether these results translate to patients at very high risk of coronary events during perioperative interruption of NOAC therapy remains unclear. A strategy with initiation of aspirin therapy pre-operatively, performance of the operation under continued aspirin (with suspended NOAC), and re-initiation of NOAC therapy post-operatively (with discontinuation of aspirin therapy) may be evaluated and based on a multidisciplinary team decision. Again, further studies are required to help guide the perioperative management in these high-risk situations.

**Restarting NOAC therapy after an invasive procedure**

After a procedure with immediate and complete haemostasis, NOACs can generally be resumed 6–8 h after the end of the intervention. However, in some surgical interventions resuming full dose anticoagulation within the first 48–72 h after the procedure may carry a bleeding risk which outweighs the risk of AF-related embolism. In such cases, postoperative thromboprophylaxis using LMWH in prophylactic dose 6–8 h after surgery and delay of therapeutic anticoagulation by deferring restart of the NOAC >48–72 h can be considered. Similarly, in patients in whom oral drug intake is not possible (e.g. in the case of artificial ventilation, postoperative nausea and vomiting, ileus etc.) heparin administration should be considered. In contrast, there are no data on the safety and efficacy of the postoperative use of a reduced dose of NOACs (such as used for the prevention of venous thromboembolism after hip/knee replacement) in patients with AF undergoing a surgical procedure.

**Special considerations for selected procedures**

Special considerations for selected procedures are discussed in the Supplementary material online.

**Special considerations for atrial fibrillation ablation procedures**

Left atrial catheter ablation is an intervention with a risk of major groin bleedings as well as serious bleeding secondary to transseptal puncture (TSP) and manipulation/ablation in the left atrium (although the incidence of these complications has been decreasing, particularly in experienced centres).220 On the flipside, the intervention directly increases the risk of thromboembolic complications.220,221 Recent international consensus statements and guidelines recommend performing left atrial catheter ablation under uninterrupted anticoagulant treatment with VKA (target INR 2.0–2.5 if on VKAs),1,220 since such a strategy was associated with less thromboembolic events and less bleeding as compared to bridging with heparin.222 The efficacy and safety of uninterrupted NOAC vs. VKA therapy for AF ablation have been examined in dedicated RCTs for apixaban,223 dabigatran,224 edoxaban,225 and rivaroxaban.226 The last dose of once-daily based NOACs were recommended (rivaroxaban) or mandated (edoxaban) to be administered in the evening before the procedure, whereas twice-daily dosed NOACs (apixaban, dabigatran) were administered in the morning of the procedure.227 While substantial variations in the event rate in the VKA arm of these trials were observed, major bleedings were overall lower with NOACs without an increase in thromboembolic complications.228 A recent meta-analysis of 29 studies comprising over 12 000 patients confirmed a lower rate of bleeding events with NOACs vs. VKA at a similar (low) rate of thromboembolic complications.229 Taken together, uninterrupted NOAC therapy can be considered safe and effective in AF ablation and should likely be the preferred mode of anticoagulation for patients undergoing this procedure.

An institutional protocol for NOAC patients undergoing AF ablation should be developed to ensure a uniform approach. To mimic the trial situation as closely as possible, switching NOAC intake to the evening well in advance (e.g. 1 week) of the intervention may be reasonable for the once-daily based NOACs edoxaban and...
rivaroxaban.\textsuperscript{225,226} Whether opting to administer the last NOAC dose shortly before the procedure (i.e. truly uninterrupted) for BID dosed NOACs or to go for a short cessation period (last NOAC dose on the evening before the procedure), may depend on a number of factors including renal function, a routine practice of heparin administration prior to (first) TSP, and administration of protamine prior to sheath removal.\textsuperscript{9,220,229} Indeed, particular in the latter case, patients may be exposed to low anticoagulant levels following the procedure if the morning dose is withheld.\textsuperscript{227} RCT-based evidence comparing ‘truly-’ and ‘minimally’ interrupted NOAC strategies, however, is not available. In the RE-CIRCUIT trial, the five major bleeding events in the dabigatran arm all occurred in patients with ≤8 h (n = 2) or 8–48 h (n = 3) since last intake of dabigatran. Moreover, 19.6% of all patients on dabigatran had their last intake of the drug >8 h prior to the procedure resulting in a similar duration of interruption as in QD NOACs with last intake on the evening before the procedure. Skipping the morning dose on the day of the ablation may hence be a valid option in BID-dosed NOACs (Figure 16).

Routine exclusion of LA/LAA thrombus prior to AF ablation is recommended according to current expert consensus statements and guidelines also in NOAC treated patients, especially in patients presenting for the procedure without anticoagulation.\textsuperscript{1,230} 

During the ablation, intravenous heparin should be administered to achieve an ACT of 300–350 s.\textsuperscript{230} It has been noted that the total need for heparin and the time to target ACT was higher in some NOAC- (particularly FXa-inhibitor-) treated patients.\textsuperscript{226,252,233} Indeed, dabigatran readily prolongs ACT measurements whereas the effect of FXa inhibitors are variable depending on the assay used.\textsuperscript{234} The clinical implications of this, however, are currently unclear. It may hence be reasonable to use the same target ACT levels for heparin titration in NOAC-treated patients as in patients on (uninterrupted) VKA.

NOAC intake can be resumed 3–5 h after sheath removal if adequate haemostasis is established and pericardial effusion has been ruled out.\textsuperscript{229}

**Special considerations for cardiac surgery procedures**

**Cessation and re-initiation of NOACs around cardiac surgery**

Elective cardiac surgery in patients on NOACs fall into the ‘red’ category of procedures with high risk (i.e. with a risk of frequent and/or high impact bleeding), as indicated in Table 12 and Figures 14 and 15. Hence, a standard interruption time of 48 hours applies, also according to the European Association for Cardio-Thoracic Surgery (EACTS) Guidelines, but longer interruption times of 72–96 h may be considered in patients at risk of NOAC accumulation (e.g. older patients, CKD etc.). Of note, if NOACs are interrupted for >72 h the likelihood of any residual NOAC level appears very low,\textsuperscript{162,211} usually precluding consideration of NOAC level assessment outside scenarios with very high risk of drug accumulation (e.g. severely reduced renal function). Importantly, and as for most other situations, pre-operative bridging with LMWH is not advised for elective patients on NOACs.

In patients on NOACs who need to **urgently** undergo cardiac surgery, i.e. without the possibility to interrupt treatment for the above-mentioned intervals, assessment of NOAC plasma levels may be helpful for risk stratification (see Figure 12). EACTS guidelines suggest plasma levels <30 ng/mL as cut-off values below which operations may ‘safely’ be performed, but prospective outcome data are lacking.\textsuperscript{226} If higher values are measured and further waiting is impossible, reversal of dabigatran using idarucizumab may represent a valid treatment option.\textsuperscript{181} It is currently unclear if reversal of FXa inhibitors using andexanet alpha is similarly safe and effective in such situations, particularly given its potential pro-thrombogenic effect as well as its non-specific inhibitory effect on other FXa inhibitors including UFH (which may require the use of a direct thrombin inhibitor such as argatroban or bivalirudin during cardiopulmonary bypass).\textsuperscript{236} In view of these limitations, combined with the limited availability and high cost of andexanet alpha, FXa inhibitor ‘reversal’ using PCC or aPCC may be advisable, also carefully weighing its indication against its potential prothrombotic effect, until further data for andexanet alpha become available in the context of cardiac surgery procedures.\textsuperscript{235,237}

Following cardiac surgery, the optimal time point for NOAC (re-)initiation depends on a number of factors, including adequate haemostasis as well as any additional interventions (planned and unplanned). Prophylactic UFH or LMWH is advisable in the initial postoperative period due to its rapid onset and offset as well as its reversibility, followed by therapeutic heparin 12–48 h postoperatively, as discussed in the section on ‘Patients undergoing a planned invasive procedure, surgery, or ablation’.\textsuperscript{235} Once adequate haemostasis has been confirmed and no further interventions are planned, UFH or LMWH may be transitioned to a NOAC in eligible patients (Tables 1 and 4; excluding, importantly, patients after mechanical valve replacement as well as patients after bioprosthetic valve implantation or valve repair as discussed below).

**NOAC management around interventions following cardiac surgery**

**(including chest tube insertion, removal of temporary epicardial pacing wires)**

There are no strong data to advise on how to best deal with interventions performed or planned to be performed shortly after cardiac surgery, including removal of temporary epicardial pacemaker wires. In most scenarios, a similar scheme as for ‘low bleeding risk’ interventions can be applied (Table 12, Figures 14 and 15), i.e. with a 24 h interruption of NOAC therapy. However, a host of other factors may influence the duration of NOAC interruption including thrombocytopenia, additional antplatelet therapy, co-medications, deterioration of CKD etc. It may hence be advisable to not initiate NOAC therapy following cardiac surgery prior to temporary pacing wire removal or when any other intervention (drainage of pleural effusion etc.) is still anticipated.

**NOAC use in post-operative AF**

Post-operative AF is common following cardiac surgery, with incidences reported as high as 20–50%.\textsuperscript{1,238} The 2020 ESC AF guidelines (developed in collaboration with the EACTS) indicate that long-term OAC therapy may be considered in patients at risk for stroke with (newly developed) postoperative AF after cardiac surgery (Class IIb, level of evidence B), since both the short- and long-term risk of stroke may be substantially elevated in such patients.\textsuperscript{1,239} The timing of OAC/NOAC initiation follows the general principles after cardiac surgery as outlined above.
NOAC use in patients with AF after bioprosthetic valve implantation or valve repair

Traditionally, VKA have been the anticoagulants of choice during the first 1–3 months after bioprosthetic valve implantation or valve repair in patients with AF.\textsuperscript{235} As discussed in 'NOAC eligibility and dosing' section, NOACs appear as a valid option after this period given data from the pivotal phase III studies as well as the dedicated RIVER trial.\textsuperscript{12,17,19,20,24} Results of the latter imply that patients may be treated with a NOAC even earlier after biological valve replacement, but the number of patients randomized <3 months post-operative was small ($n = 95$, on rivaroxaban). Further confirmatory data, also with other NOACs, are needed.

Practical aspects on the use of NOACs after TAVI implantation are covered in the 'NOAC eligibility and dosing' section (see also Table 1).

NOACs after coronary artery bypass grafting

In patients without AF, dual antiplatelet therapy (DAPT) is frequently administered to patients following coronary artery bypass grafting (CABG), as it has been associated with improved vein graft patency and reduced mortality (although the level of evidence especially for the latter is weak).\textsuperscript{240–242} In patients with concomitant AF, the combination of a single antiplatelet agent (aspirin or clopidogrel) with a NOAC appears reasonable but—in contrast to patients after percutaneous coronary intervention (PCI)/acute coronary syndrome (ACS) (see ‘Patients with atrial fibrillation and coronary artery disease’ section)—randomized trial evidence is not available. The combination of DAPT with a NOAC seems undesirable due to its inherent bleeding risk, but again, no prospective evidence is available. The timing of post-operative initiation of NOAC therapy follows the same principles as indicated above. One year post-CABG, NOACs may be continued as monotherapy, similar to other patients with chronic coronary syndrome (CCS).\textsuperscript{243}

NOACs after surgical AF treatment ± LAA occlusion/exclusion

According to the 2020 ESC AF guidelines (developed in collaboration with EACTS), long-term OAC therapy is recommended in patients after AF surgery and appendage closure based on the patient’s thromboembolic risk as assessed by the CHA\textsubscript{2}DS\textsubscript{2}-VASc score and not on the ‘success’ of the procedure (no RCT data).\textsuperscript{1} Post-operative initiation of NOAC therapy follows the general principles after cardiac surgery as outlined above.

Patients with atrial fibrillation and coronary artery disease

The combination of AF and CAD is not only a common clinical scenario, it is also a complex setting to combine anticoagulation and antiplatelet therapy. According to the 2020 ESC guidelines AF patients with relevant CAD have at least a CHA\textsubscript{2}DS\textsubscript{2}-VASc score of 1 (and mostly higher due to the presence of other cardiovascular risk factors) and hence an indication for OAC. The convention is that a period of DAPT (i.e. aspirin and a P2Y\textsubscript{12} inhibitor) is necessary to prevent stent thrombosis or recurrent events after an ACS and/or stenting for CAD—but that this is not sufficient for stroke prevention. Conversely, NOACs are essential for stroke prevention but on their own insufficient for preventing new coronary events in the immediate phase after ACS or stenting. The choice of antithrombotic drug combinations therefore represents a clinical conundrum: too little and risk a coronary event and/or stroke, too much and risk a bleeding event.
**Triple vs. dual therapy**

**NOACs vs. VKA in dual vs. triple therapy**
Four dedicated prospective RCTs have addressed the issue of using a NOAC or VKA in a variety of combinations with antiplatelet agents to reduce bleeding events after PCI and/or an ACS in patients with AF.\(^{244-247}\) In essence, these trials focused on bleeding as the primary endpoint, with coronary events and stroke as important secondary outcomes. On aggregate, these studies showed that dual therapy with a NOAC plus a P2Y\(_{12}\) inhibitor reduced the risk of bleeding compared to triple therapy with VKA, aspirin and a P2Y\(_{12}\) inhibitor (mostly clopidogrel). This bleeding risk reduction appeared to be driven by both receiving a NOAC instead of VKA as well as by omitting aspirin,\(^ {244}\) and this benefit was also observed in medically managed ACS/PCI patients with AF.\(^ {244,248}\)

NOAC-based dual therapy also seems to be safe in terms of coronary ischaemic risk although the evidence is less strong as such events were relatively rare in all four studies which (as a result) were underpowered for thrombotic events analyses.\(^ {244-247}\) While a recent network meta-analysis indicated that, on aggregate, a NOAC plus a P2Y\(_{12}\) inhibitor reduces bleeding risk without significantly increasing coronary thrombotic risk compared to any other regimen that includes DAPT,\(^ {249}\) several other meta-analyses including the four NOAC RCTs indicate that there might be a small but statistically significant increase in the risk of coronary (but not stroke) events when omitting aspirin.\(^ {250-253}\)

**Duration of triple therapy after ACS/PCI**
According to the current 2020 ESC guidelines for AF as well as for non-ST-elevation acute coronary syndrome (NSTE-ACS), a short course of triple therapy is recommended for up to 1 week in all patients with AF undergoing PCI\(^ {1,254}\). In medically managed NSTE-ACS patients, combination of a NOAC with only a single antiplatelet agent (preferably clopidogrel) is recommended from the event onwards.\(^ {254}\) However, the time frame of inclusion for the four aforementioned NOAC RCTs ranged from several hours after PCI up to >10 days. As such, a selection bias towards lower-risk patients cannot be excluded; furthermore, a variable course of triple therapy may have been given to a substantial number of patients subsequently randomized to NOAC-based dual therapy. Finally, although bleeding events were consistently reduced across the four NOAC trials by NOAC-based dual therapy this did not translate into a reduction in all-cause mortality (as compared to VKA-based triple therapy). Therefore, a low threshold for prolonging triple therapy with DAPT and a NOAC up to 30 days may be advisable in patients with a high atherothrombotic risk, including those after a complex PCI or with a history of stent thrombosis. In contrast, continuation of triple therapy beyond 30 days rarely seems warranted.\(^ {255}\)

The choice of anticoagulant as well as the duration of triple (and dual) therapy hence needs to be personalized based on atherothrombotic-, cardioembolic-, and bleeding risk.\(^ {75}\) It is highly recommended to formally assess stroke and cardiac ischaemic event risk...
using validated tools such as the CHA2DS2-VASc and Global Registry of Acute Coronary Events (GRACE) scores.\textsuperscript{1,75} Estimating the bleeding risk should lead to efforts to correct or reduce reversible bleeding risk factors. Proton pump inhibitors should be encouraged in all patients with a combination of antiplatelets and anticoagulants.

**NOAC dosing in the context of dual/triple therapy**

It is unknown whether rivaroxaban 15 mg QD (dose reduced to 10 mg QD in patients with moderately reduced renal function) as used in the ‘Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention’ (PIONEER) trial is sufficient for stroke prevention in patients with ACS and/or undergoing PCI as the trial (like the other three NOAC trials) was underpowered for individual efficacy outcomes.\textsuperscript{246} In contrast, approved stroke-preventive doses of NOACs were tested for apixaban (5 mg BID), dabigatran (110/150 mg BID), and edoxaban (60 mg QD) in the respective dual vs. triple therapy trials; in all three trials doses were reduced according to the respective standard criteria.\textsuperscript{244,245,247} NOAC dosing therefore should follow the general published and approved criteria with dose reduction be performed according to the individual NOAC’s dose reduction criteria.\textsuperscript{1}

Adding a very low dose of rivaroxaban (2.5 mg BID) decreased ischaemic events including stent thrombosis as compared to DAPT alone in ACS patients without AF (albeit with an increase in bleeding).\textsuperscript{115} The same dose was used in the NOAC ‘triple’ therapy arm in the PIONEER study;\textsuperscript{246} its protective effect against AF-related stroke, however, remains undetermined making this strategy unsuitable for AF patients after an ACS/PCI.

**Choice of P2Y12 inhibitor**

In the 2020 ESC AF guidelines, the use of ticagrelor or prasugrel as part of a triple therapy regimen is discouraged.\textsuperscript{1} Ticagrelor increases bleeding risk in patients on dual therapy when compared to clopidogrel.\textsuperscript{256} Although only few patients have been included with a P2Y12-inhibitor other than clopidogrel into the above-mentioned RCTs, the benefit in terms of reduced bleeding risk with NOAC-based dual therapy compared to VKA-based triple therapy appears to be maintained regardless of the type of P2Y12 inhibitor.\textsuperscript{256} In post-ACS patients at high coronary thrombotic risk and low bleeding risk in whom otherwise a VKA- or NOAC-based triple therapy would be warranted, dual therapy with a NOAC plus ticagrelor could be considered instead. Further data, including dedicated RCTs, are
warranted in this area. Indeed, up to 40% of patients on clopidogrel may reach insufficient platelet inhibition.\textsuperscript{257} It is unknown whether measuring the antiplatelet response to clopidogrel when considering omitting aspirin, and adapting the strategy (e.g. switching to ticagrelor or re-introducing aspirin) will result in a net benefit in this setting.

Treatment of patients with chronic coronary syndrome

Until recently, there were only indirect data from the pivotal phase 3 NOAC trials as well as some observational data on whether it might be safe to transition to NOAC monotherapy in patients with CCS.\textsuperscript{258} The Japanese multi-centre, open-label ’Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease’ (AFIRE) trial demonstrated that continuing rivaroxaban 15 mg QD monotherapy beyond 1 year after a revascularization procedure in AF patients not only decreased the risk of ISTH bleeding (primary safety outcome) but also demonstrated non-inferiority for the primary composite endpoint of cardiovascular events (stroke, systemic embolism, MI, unstable angina requiring revascularization) or death from any cause compared with the combination of rivaroxaban and antiplatelet therapy.\textsuperscript{259} Indeed, the trial was stopped prematurely due to an increased mortality in the combination therapy arm.\textsuperscript{259} Although it is formally unclear if these results translate to other NOACs, other doses, and other populations, these data suggest that most AF patients with chronic CAD should be transitioned to NOAC monotherapy without an antiplatelet agent as recommended in current ESC AF guidelines (Figure 17).\textsuperscript{1}

Creation of local standard operating procedures is strongly advised for the management of patients with AF and ACS or CCS, based on the available evidence and recent ESC AF- and Non-ST-Elevation Acute Coronary Syndrome (NSTE-ACS) Guidelines.\textsuperscript{1,254}

Scenario 1: coronary interventions in atrial fibrillation patients on non-vitamin K antagonist oral anticoaguants

Performing a PCI (scheduled or not) under NOAC is different than under VKA for several reasons, and various aspects and uncertainties need to be taken into consideration, including:

- timpoint of the last dose, adherence, and renal function;
- variability in renal function in an acute setting;
- singular factor II or Xa blockade vs. multifactor antagonism;
- uncertainty about the extent of anticoagulation in the absence of established tests, and hence
- uncertainty about stacking of additional periprocedural anticoagulants, etc.

Temporary discontinuation of the short-acting NOACs may allow for safe initiation of antiplatelet therapy and standard local

---

![Cardioversion workflow in AF patients treated with NOAC, depending on the duration of the arrhythmia and prior anticoagulation.](https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euab065/6247378)

*Figure 19* Cardioversion workflow in AF patients treated with NOAC, depending on the duration of the arrhythmia and prior anticoagulation. AF, atrial fibrillation; CV, cardiovascular; LA, left atrium; LAA, left atrial appendage; NOAC, non-vitamin K antagonist oral anticoagulant.
anticoagulation practices peri-procedurally (Figure 18). In contrast, NOACs should be continued in non-invasively managed ACS patients.

New-generation drug-eluting stents are preferred to shorten exposure to dual or triple therapy after the procedure but also to avoid the need for repeat interventions. Sole balloon angioplasty or bypass surgery should always be considered as an alternative in patients in need for chronic anticoagulation since they can reduce the need for long-term dual or triple therapy. There is no longer a reason to opt for a bare metal stent as a strategy to reduce DAPT duration. 260–262

The specific discussion of the possible scenarios (elective PCI, NSTE-ACS, ST-elevation myocardial infarction) is provided in the Supplementary material online and summarized in Figure 18.

Scenario 2: management of the patient with a recent acute coronary syndrome (<1 year) who develops new-onset atrial fibrillation

ACS guidelines recommended DAPT for up to 1 year after the acute event in patients without indication for OAC, and high-risk patients might require an even longer DAPT duration. 263,264 In high bleeding-risk ACS patients, however, current ESC guidelines allow for shorter DAPT durations (3–6 months). 25,265 If AF develops during the first year after an ACS and there is an indication for anticoagulation, a NOAC should be started and the need for continuing DAPT should be carefully weighed against the increased bleeding risk. Beyond 1 month after the event, aspirin can be stopped in the majority of such patients as discussed above.

Scenario 3: a chronic coronary syndrome patient (acute coronary syndrome ≥1 year ago) develops atrial fibrillation

Patients with a CCS developing AF should receive anticoagulation, depending on their CHA2DS2-VASc score (which per definition will be ≥1). A NOAC without any antiplatelet agent appears to be the preferred strategy for these patients as discussed above, based on the results of the four landmark NOAC trials (which included up to 15–20% of patients with a prior MI) and the ‘Atrial Fibrillation and Ischaemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease’ (AFIRE) trial. 259 An additional antiplatelet agent should only be considered in individual patients with a very high ischaemic- and low bleeding risk.

Treatment of left ventricular thrombus after myocardial infarction in patients with atrial fibrillation

In the absence of randomized studies, it remains uncertain whether a NOAC is effective in the treatment of left ventricular thrombi complicating a large infarction. One observational study suggests that NOACs were associated with a higher incidence of thromboembolic events compared to VKA in (mostly non-AF) patients with a left ventricular thrombus, while others showed a similar rate of thrombus resolution. 266–269 Although residual confounding can never be excluded in these settings, VKA should be viewed as standard of care for the treatment of patients with LV thrombus until more data are available. Only in very special situations (e.g. no VKA monitoring possible, no stable INR despite maximal efforts, etc.) NOACs may be evaluated after clear communication and consent from the patient about the lack of data and the off-label situation.

Cardioversion in a NOAC-treated patient

Based on current ESC guidelines, 1 in patients with AF of >48 h (or unknown) duration undergoing electrical or pharmacological cardioversion, effective OAC needs to be established for at least 3 weeks prior to cardioversion or a pre-cardioversion transoesophageal echocardiography (TOE) needs to rule out left atrial thrombi, irrespective of the CHA2DS2-VASc score. 1,227 Different scenarios have to be distinguished: electrical cardioversion in a patient who is on chronic treatment with a NOAC and now requires cardioversion, and cardioversion in a patient not on anticoagulation (Figure 19).

Considerations regarding the practical management of patients cardioverted after ≥3 weeks of NOAC treatment, as well as of patients with >48 h or ≤48 h AF without NOAC therapy are summarized in Figure 19 and in the Supplementary material online.

Duration of anticoagulation post-cardioversion

Oral anticoagulation post-cardioversion should be continued as per the recommendations provided in the ESC AF guidelines. 1 The long-term management of patients post-cardioversion depends on the individual patient’s CHA2DS2-VASc score. Men and women with a CHA2DS2-VASc ≥2 and ≥3, respectively, have a Class I recommendation for long-term anticoagulation independent of the ‘success’ of cardioversion. 1 This is also true for AF with a clear ‘trigger’ including pulmonary embolism, sepsis, or major surgery, since the trigger does not negate underlying structural or vascular factors associated with increased thromboembolic risk. For AF of >48 h duration and a low CHA2DS2-VASc score (0 in men, 1 in women) anticoagulation needs to be continued for 4 weeks post-cardioversion.

In contrast, it is currently unknown how long (if at all) the latter patients should be anticoagulated if AF is of shorter duration (especially when <12–24 h). Indeed, these patients may in addition have shorter, self-limiting (i.e., ‘self-cardioverting’) episodes of AF for which the optimal anticoagulation strategy is currently unclear. Given the overall low risk of thromboembolism in these patients, longer and particularly life-long anticoagulation generally does not seem to be mandated. 227 Current AF guidelines indicated the possibility to drop post-cardioversion anticoagulation in patients with a definite duration of AF ≤24 h and a very low stroke risk (CHA2DS2-VASc of 0 in men or 1 in women). 1

Management of a patient with documented left atrial appendage thrombus

Patients in whom TOE identifies a left atrial thrombus should not undergo cardioversion. There are no (and likely never will be any) adequately powered prospective endpoint trials to investigate the best anticoagulation strategy (including NOAC vs. VKA) in this scenario.
Previously, standard therapy consisted of VKA therapy (with heparin bridging if necessary) with rigorous follow-up and INR monitoring until resolution of the thrombus. One prospective study indicated a thrombus resolution rate of 41.5% (22 of 53 patients) with standard dose rivaroxaban (20 mg/d) — comparable to a retrospective registry in which left atrial thrombus resolution was observed in 60 of 96 patients (62.5%) in heparin/warfarin treated patients. A small study also showed complete thrombus resolution with dabigatran 150 mg BID in 17 of 19 patients (89.5%) vs. 17 of 22 patients (77.3%) on warfarin.271 Another prospective study with dabigatran (NCT02256683) finished inclusion but study outcomes have not been reported yet. In the 'Eliquis evaluated in acute cardioversion compared to usual treatments for anticoagulation in subjects with NVAF' (EMANATE) trial, thrombus resolution rate was similar in patients treated with apixaban (52%, 12/23) as with LMWH/VKA (56%, 10/18).272 This is supported by observational evidence indicating a similar degree of thrombus resolution using a NOAC vs. a LMWH/VKA based regimen.227,273–275 Together, these data indicate that using NOACs for left atrial thrombus resolution may be an option (most data available for apixaban and rivaroxaban), particularly in patients where a VKA is not well tolerated or adequate INR control cannot be obtained. If a thrombus persists during follow-up despite confirmed good adherence to the NOAC regimen an individualized management strategy is required. This may include switching to a different type of NOAC (direct thrombin inhibitor to FXa-inhibitor or vice versa) or INR-tailored VKA-therapy. Some centres have reported LAA closure in patients with a persistent thrombus.276 Finally, long-standing thrombi may become organized and fixed, allowing cardioversion if regaining sinus rhythm is considered to be of substantial benefit for the patient outweighing any residual thromboembolic risks. All of the aforementioned strategies are lacking strong evidence and further studies are clearly required in this field.

AF patients presenting with acute stroke while on NOACs

The incidence of ischaemic stroke is 1–2% per year in AF patients treated with a NOAC. Stroke may occur despite good adherence to drug treatment but NOAC plasma concentration may correlate both with stroke severity (as is the case with INR in patients on VKA) and large vessel occlusion.277 Case series and observational studies reveal an adequate NOAC dose at ischaemic stroke-onset is associated with milder severity and more favourable outcome compared to non-anticoagulated stroke patients with AF.278,279 Intracerebral bleeding (ICB) accounts for 8–15% of stroke in Europe and the USA. 15–25% of all ICBs are related to OAC.280,281 RCTs indicate an ICB incidence of 0.13–0.37% per year in AF patients on NOAC treatment, while the incidence of intracranial haemorrhage (ICH; also including subarachnoid, epidural and subdural
haemorrhage) is 0.23–0.55% per year.47,170,282–284 A retrospective analysis of the USA ‘Get With the Guidelines-Stroke’ and a national Japanese database found a more favourable outcome with NOACs compared to VKA, contrasting previous studies reporting similar outcomes and a mortality rate of 25–40% after NOAC-related ICB.285,286

All stroke patients on NOAC treatment require immediate neurologist/stroke physician input to decide on the best therapeutic approach.

Management of NOAC treated AF patients in the acute phase of stroke
The management of AF patients on NOACs in the acute phase of ischaemic stroke is summarized in Figure 20 as well as in the Supplementary material online. The management of AF patients on NOACs in the acute phase of an intracranial bleeding is discussed in the Supplementary material online.

Management in the post-acute phase of stroke patients with AF
AF patients post-ischaemic stroke or transient ischaemic attack
Alternative (and treatable) causes of stroke have to be assessed in every AF patient.279,287 No RCT evidence exists favouring one NOAC over another or to switch one NOAC to another in patients with transient ischaemic attack (TIA) or ischaemic stroke on NOAC therapy. Treatment needs to be individualized with appropriate dosing and assessment of patient specific co-morbidities and co-medication (see ‘NOAC eligibility and dosing’ section). Measurement of NOAC plasma levels at the time of hospital admission may help assess adherence at least at the time of stroke.

Since stroke-related disruption of the blood–brain barrier increases the risk of secondary haemorrhagic transformation, timing of (re-)starting OAC must balance the risk of recurrent ischaemic stroke vs. risk of parenchymal bleeding. Data from large RCTs are missing, as phase III trials of NOACs excluded patients within 7–30 days after stroke and within 3–6 months after severe stroke.280 As RCTs are ongoing, current recommendations are based on consensus opinion,11,288 observational studies,289–291 and an individual patient data analysis of prospective cohort studies.292 The 2020 ESC guidelines on the management of AF state that OAC ‘should be (re-)initiated as soon as considered possible from the neurological perspective (in most cases within the first 2 weeks)’.1 The 2019 AHA/ASA guidelines conclude that ‘for most patients with an [acute ischaemic stroke] in the setting of AF, it is reasonable to initiate OAC between 4 and 14 days after the onset of neurological symptoms’.288 A recent European Stroke Organisation (ESO) expert consensus concluded that ‘recommendations about the optimal time for initiating anticoagulation in patients with AIS’ could not be made.280

Figure 21 (Re-)initiation of anticoagulation after TIA/stroke. Without proven evidence/RCT data available, based on expert opinion. Consider inclusion of patient in an ongoing trial. (Re-)start only in the absence of contraindications and if stroke size is not expected to substantially increase the risk of secondary haemorrhagic transformation. Consider shorter delays to (re-)start a NOAC in case of a very high risk of stroke recurrence [e.g. LA(A) thrombus] and no haemorrhagic transformation on follow-up brain imaging (using CT or MRI). CT, computed tomography; LA, left atrium; LAA, left atrial appendage; MRI, magnetic resonance imaging; NOAC, non-vitamin K antagonist oral anticoagulant; RCT, randomized clinical trial; TIA, transient ischaemic attack.
At present, several randomized trials [e.g. ELAN (NCT03148457), OPTIMAS (NCT03759938), TIMING (NCT02961348). START (NCT03021928), AREST (NCT02283294)] focusing on early vs. late (re-)starting of a NOAC after acute ischaemic stroke are underway with results expected in 2021/22.290 In the interim practical guidance on (re-)starting of a NOAC after acute ischaemic stroke are underway (NCT03021928), AREST (NCT02283294) focusing on early vs. late OPTIMAS (NCT03759938), TIMING (NCT02961348), START.

---

**Figure 22** (Re-) initiation of anticoagulation post intracranial bleeding. *Without RCT evidence; ideally include patient in an ongoing trial. aBrain imaging mandatory before (re-)initiation of (N)OAC. NOAC, non-vitamin K antagonist oral anticoagulant; PCI, percutaneous coronary intervention.

---

**AF patients with ischaemic stroke and concomitant atherosclerosis**

Addition of antiplatelets to a NOAC for a specified period may be necessary or considered in selected AIS patients with AF, if stroke is most probably caused by large-vessel disease [i.e. ‘symptomatic’ (intracranial) stenosis], or the patient has recently undergone a stenting procedure, and bleeding risk is considered to be low. However, evidence for this approach is lacking and further studies are required.296 AF patients with acute ischaemic stroke due to ‘symptomatic’ high-grade carotid stenosis should preferably undergo carotid endarterectomy (CEA), as carotid stenting necessitates (dual) antiplatelet therapy in addition to OAC with a subsequently higher risk of bleeding.296 In AF patients undergoing CEA, aspirin is recommended prior to and for some days after surgery but usually should be stopped on resuming NOAC therapy. AF patients with asymptomatic atherosclerosis or stenosis of the internal carotid and/or intracranial arteries should be treated with a statin and OAC, without the need for additional antplatelet therapy, similar to the situation in stable coronary artery disease (see ‘Patients with atrial fibrillation and coronary artery disease’ section).

**AF patients post-intracranial haemorrhage**

**AF patients post-intracerebral bleeding**

In addition to its immediate prognosis, ICB in the setting of AF is also associated with later ischaemic stroke and mortality, partly due to the cessation of anticoagulation after ICB. However, a history of a spontaneous ICB constitutes a contraindication for anticoagulation according to labelling of VKAs and NOACs, unless the cause of the bleeding (like uncontrolled hypertension, aneurysm or arteriovenous malformation, or medical ‘triple’ therapy) has been reversed.

Evidence-based guidelines regarding use of NOACs in AF patients post-ICB are not available but several RCTs are ongoing [PRESTIGE-AF (NCT03996772); APACHE-AF (NCT02565693); NASPAPAF-ICH (NCT02998905); ASPIRE (NCT03907046); SoSTART (NCT03153150); A1ICH (NCT03243175); ENRICH-AF (NCT03950076)]. Present knowledge is based on observational (mostly retrospective) data with varying proportions of ICB-patients with AF re-starting OAC, predominantly or exclusively with VKA.1,280,297–299 Observational studies including AF patients with a history of ICB showed that restarting OAC with a NOAC vs. VKA...
was associated with similar to lower rates of ischaemic stroke without difference (or even lower) rates of recurrent ICB.\textsuperscript{300,301} However, publication and selection bias as well as residual confounding must be taken into account as with all observational non-randomized studies.\textsuperscript{297} The ESO Karolinska Stroke Update Conference consensus paper states that in selected ICB patients (re-)initiation of OAC compared to no OAC may improve outcomes (Grade C), and that ‘NOACs should preferentially be used over VKA’ (Grade C).\textsuperscript{293} A recent ESO guideline concludes that ‘restoring oral anticoagulation can be considered after careful weighing of risks and benefits’.\textsuperscript{280}

Therefore, as stated in the 2020 ESC AF guidelines, a case-by-case consideration is needed whether or not to (re-)introduce anticoagulation of any type in patients who have experienced an OAC-related ICB (Figure 22).\textsuperscript{1} Adequate blood pressure control is of paramount importance in all patients post ICB. Whether genetic polymorphisms, like the apolipoprotein E genotype, or low-density lipoprotein cholesterol levels predict the likelihood of recurrent ICB has to be proven by prospective trials.\textsuperscript{302–304} Patients with cerebral amyloid angiopathy have a very high risk of recurrent ICB and should not be anticoagulated.\textsuperscript{305}

Analogous to the management of VKA-related ICB, NOACs may be re-started 4–8 weeks after ICB, if the individual risk of cardio-embolic stroke is high and the risk of recurrent ICB is estimated to be lower.\textsuperscript{281,297,306}

LAA occlusion is a potential alternative strategy to long-term anticoagulation in AF patients post ICB after careful weighing of risks and benefits, as outlined in the 2020 ESC AF guidelines and ESO recommendations.\textsuperscript{1,280,293} However, this strategy requires a period of anti-platelet or anticoagulant treatment post-deployment, which also carries a risk of recurrent ICB. The safety and effectiveness of shorter duration antiplatelet therapy is unknown. RCT evidence for LAA occlusion after OAC-related ICB is lacking as the number of AF patients with previous ICB in most randomized studies is not reported.\textsuperscript{307} Patients with AF after ICB in whom LAA occlusion is being considered should ideally be included into an ongoing RCT such as ‘Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation and High Risk of Stroke and Bleeding Compared to Medical Therapy: a Prospective Randomized Clinical Trial’ (CLOSURE-AF, NCT03463317), ‘Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage’ (STROKECLOSE, NCT02830152), or ‘Comparison of LAA-Closure vs. Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding’ (CLEARANCE, NCT04298723).

### AF patients post-subarachnoid haemorrhage

Incidence of subarachnoid haemorrhage (SAH) was <0.1% per year in AF patients on NOAC treatment in RCTs.\textsuperscript{170,282,283} There is little evidence to guide the resumption of OAC treatment in patients with

<table>
<thead>
<tr>
<th><strong>Table 13 NOAC use in frail patients</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Very Fit</strong></td>
</tr>
<tr>
<td>People who are robust, active, energetic and motivated. These people commonly exercise regularly. They are among the fittest for their age.</td>
</tr>
<tr>
<td><strong>Well</strong></td>
</tr>
<tr>
<td>People who have no active disease symptoms but are less fit than category 1. Often, they exercise or are very active occasionally, e.g. seasonally.</td>
</tr>
<tr>
<td><strong>Managing Well</strong></td>
</tr>
<tr>
<td>People whose medical problems are well controlled but are not regularly active beyond routine walking.</td>
</tr>
<tr>
<td><strong>Vulnerable</strong></td>
</tr>
<tr>
<td>While not dependent on others for daily help, often symptoms limit activities. A common complaint is being “slowed up”, and/or being tired during the day.</td>
</tr>
<tr>
<td><strong>Mildly Frail</strong></td>
</tr>
<tr>
<td>These people often have more evident slowing and need help in high order with ADLs (finances, transportation, heavy housework, medications). Typically, mild frailty progressively impairs shopping and walking outside alone, meal preparation and housework.</td>
</tr>
<tr>
<td><strong>Moderately Frail</strong></td>
</tr>
<tr>
<td>People need help with all outside activities and with keeping house. Inside, they often have problems with stairs and need help with bathing and might need minimal assistance (cuing, standby) with dressing.</td>
</tr>
<tr>
<td><strong>Severely Frail</strong></td>
</tr>
<tr>
<td>Completely dependent for personal care, from whatever cause (physical or cognitive). Even so, they seem stable and not at high risk of dying (within ~ 6 months).</td>
</tr>
<tr>
<td><strong>Very Severely Frail</strong></td>
</tr>
<tr>
<td>Completely dependent, approaching the end of life. Typically, they could not recover even from a minor illness.</td>
</tr>
<tr>
<td><strong>Terminally Ill</strong></td>
</tr>
<tr>
<td>Approaching the end of life. This category applies to people with a life expectancy &lt;6 months, who are not otherwise evidently frail.</td>
</tr>
</tbody>
</table>

The ‘Canadian Study of Health and Aging’ (CHSA) Clinical Frailty Scale, based on comprehensive geriatric assessment including structured interview (http://www.csha.ca and Ref.\textsuperscript{338}). The decision to anticoagulate frail patients depends on multiple aspects (see text for details). While fit or mild frailty per se generally does not pose a problem (green), severe frailty and terminal illness typically indicate a contraindication to anticoagulation (red).
AF following SAH.\textsuperscript{308} Thorough angiographic evaluation, treatment of any underlying aneurysm or arteriovenous malformation and multidisciplinary team (neurological/neurosurgical/neuro-radiological) evaluation of future risk of re-bleeding is needed prior to any consideration to restart OAC in the AF patient after a SAH. When SAH occurs in AF patients taking a NOAC in the absence of a remediable aetiology it seems prudent not to re-initiate OAC treatment. LAA closure may be considered (no RCT data available), ideally in the framework of a randomized trial.

**AF patients post-epidural haematoma or subdural haematoma**

In RCTs, incidence of subdural and epidural haematoma in AF patients on NOAC treatment was <0.2% and <0.1% per year, respectively.\textsuperscript{170,282,283} Although there are no specific data, it appears to be safe to start or reinitiate OAC about 4 weeks after (surgical removal of) traumatic epidural or subdural haematoma (SDH), particularly in the absence of drug-/alcohol abuse or a substantial risk of falling (see ‘NOACs in advanced age and frailty’ section).\textsuperscript{308} According to clinical presentation and haematoma extension, brain imaging (using CT or MRI) is recommended before (re-)starting OAC. However, adequately dosed NOAC or no anticoagulation at the time of non-traumatic epidural or SDH does not support (re-)initiation of OAC despite the fact that the risk of ischaemic stroke is increased within 4 weeks after non-traumatic SDH according to a retrospective US cohort study.\textsuperscript{309}

### NOACs in advanced age and frailty

#### NOACs in older populations

The incidence of AF rises steadily with age; by 2050, 4.4% of the world population will be older than 80 years.\textsuperscript{310,311} Stroke prevention in older AF patients is of great importance as stroke risk rises greatly with age.\textsuperscript{312} The advent of NOACs has improved prescription rates in older people, but OAC remains underutilized in up to 30% of patients with high stroke risk.\textsuperscript{313,314}

All trials of NOAC treatment in AF included significant populations of older people (defined as ≥75 years) ranging from 31% to 43% in the individual trials, comprising over 27 000 older patients in whom NOACs were studied. Rates of stroke were similarly reduced in older age groups treated with NOAC compared to VKA. Importantly, the higher absolute risk resulted in a larger absolute risk reduction by using NOACs instead of VKA in these older patients, resulting in a lower number needed to treat compared to younger patients.\textsuperscript{69,315–317} While intracranial bleeding remains lower with all NOACs compared to VKA, a significant effect of age on increased extracranial major bleeding was observed on the higher dose of dabigatran.\textsuperscript{170,318} Conversely no age interaction on rates of extracranial major bleeding was seen with apixaban, edoxaban or rivaroxaban compared to the overall trial results. In addition major bleeding appeared lower with apixaban and edoxaban compared to VKA even in older age groups.\textsuperscript{47,69,316} Observational registries in older cohorts indicate that the risk of bleeding with age appears largely consistent with trial findings to date.\textsuperscript{318–322}

Older patients with AF have more favourable outcomes on OAC than without, and on NOACs than on VKA.\textsuperscript{56,323–326} Therefore, NOACs are preferred in this cohort, consistent with current ESC guidelines.\textsuperscript{1,327,328} The net clinical benefit for OAC declines with advanced age due to competing risks for bleeding and death but is maintained longer with NOACs than VKA.\textsuperscript{329} While frailty and cognitive impairment syndromes are associated with greater mortality and underuse of OAC, the benefits of OAC are maintained in these cohorts.\textsuperscript{330} Better predictive tools may help identify those least likely to benefit due to early mortality,\textsuperscript{331} but robust evidence for reliably identifying individuals which should a priori not receive OAC are currently missing.

The ELDERCARE-AF trial represents the only placebo-controlled trial investigating a NOAC (very low-dose edoxaban, 15 mg QD) in elderly AF patients deemed unsuitable for standard OAC therapy. In this trial (conducted in Japan and confined to Japanese patients) the use of Edoxaban 15 mg QD resulted in a 4.4%/year absolute risk reduction in stroke (P < 0.001) at the cost of a non-significant absolute increase in 1.5%/year of major bleeding.\textsuperscript{102,332} It is currently unclear whether these findings translate to non-Japanese populations. If confirmed in other ethnicities, such a strategy could constitute an alternative in older patients deemed unsuitable for or higher risk with approved, full dose NOAC therapy. It would be desirable that such

### Table 14  Examples of falls risk assessment

<table>
<thead>
<tr>
<th>Presence of one or more of</th>
<th>Yes/no</th>
<th>1 point for each ‘yes’</th>
</tr>
</thead>
<tbody>
<tr>
<td>prior history of falls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>lower extremity weakness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>poor balance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cognitive impairment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>orthostatic hypotension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>use of psychotropic drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>severe arthritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dizziness</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### (B) Probability of falls assessment

<table>
<thead>
<tr>
<th>Medications</th>
<th>Yes/no</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychotropics</td>
<td>Yes/no</td>
</tr>
<tr>
<td>Low visual acuity</td>
<td>Yes/no</td>
</tr>
<tr>
<td>Diminished sensation</td>
<td>Yes/no</td>
</tr>
<tr>
<td>Near tandem stand 10 s</td>
<td>Yes/no</td>
</tr>
<tr>
<td>Alternate step test 10 s</td>
<td>Yes/no</td>
</tr>
<tr>
<td>Sit to stand 12 s</td>
<td>Yes/no</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Score</th>
<th>0–1</th>
<th>2–3</th>
<th>4–5</th>
<th>6+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probability of fall per year</td>
<td>7%</td>
<td>13%</td>
<td>27%</td>
<td>49%</td>
</tr>
</tbody>
</table>

Multidisciplinary team approach, including formal geriatric assessment recommended.

\textsuperscript{a}Adapted from Steffel et al.\textsuperscript{30}

\textsuperscript{b}Adapted from Tiedemann et al.\textsuperscript{555}
confirmatory evidence is sought as very old age remains a clinical conundrum. As discussed above, use of the lower-dose (30 mg/15 mg) vs. higher-dose edoxaban regimen (60 mg/30 mg) in the ENGAGE AF-TIMI 48 trial resulted in a 43% higher ischaemic stroke risk, while the risk of disabling or fatal strokes was similar between the two dosing regimens and the risk of major bleeding or of having a pre-defined primary net outcome event (stroke, systemic embolism, major bleeding, or death) was lower with the lower-dose edoxaban regimen. These results were consistent (and possibly even more pronounced for the primary net outcome; \( P \) interaction = 0.077) in patients \( \geq 75 \) years vs. <75 years.\(^{100}\)

In older patients the incidence of cerebral amyloid angiopathy and CMBs are more prevalent and their presence increases the risk of intracerebral haemorrhage (see ‘AF patients presenting with acute stroke while on NOACs’ section).\(^{333}\) CMBs are markers of cerebral small vessel disease and can be identified in hemosiderin sensitive brain MRI sequences. An MRI may be helpful in assessing the risk of small vessel disease and can be identified in hemosiderin sensitive stroke while on NOACs’ section).\(^{333}\) CMBs are markers of cerebral small vessel disease and can be identified in hemosiderin sensitive brain MRI sequences. An MRI may be helpful in assessing the risk of intracranial bleeding in older people especially with previous history of ICH.\(^{334,335}\) Although the prevalence of CMBs is similar, a significantly higher burden of CMBs in VKA-treated patients compared to NOAC exposure has been reported.\(^{336}\) As indicated in the 2020 ESC AF guidelines, anticoagulation should not be withheld purely based on the presence of CMBs.\(^{1}\)

**Frailty and falls**

**Frailty**

Frailty is commonly defined as a rules-based distinct phenotype and by clinical judgement of function-deficits in a frailty scale (Table 13).\(^{337–339}\) Both models identify patients at risk of or with established poor physiological reserve, high risk of falls, depression and dementia, poor physical functioning and increased mortality. Frailty and pre-frail states are common with advancing age and raise specific considerations regarding the risk-benefit of OAC. Expert consensus advocates comprehensive geriatric assessment in all older patients with frailty.\(^{340}\) Frailty is associated with weight loss and a risk for deterioration in renal function. As a result, patients need to be weighed and their renal function monitored regularly (see ‘NOACs in patients with chronic kidney disease or advanced liver disease’ section) to ensure safe NOAC dosing. There may be no benefit to OAC in states of severe frailty or where life expectancy is likely to be limited (Table 13).

**Risk of falling**

The risk of falling can be estimated using simple or more sophisticated tools (Table 14). Older patients are more likely to fall. The annual prevalence of all-cause falls and non-accidental falls in community dwelling individuals \( >75 \) years of age may be as high as 25% and 8% respectively.\(^{141}\) The rate of falls increases with polypharmacy and institutional care.\(^{342}\) Falls have often been considered a contraindication to OAC due to risk of ICH.\(^{343}\) A Markov decision analytic model published in 1999 demonstrated a patient would have to fall 295 times in order for the risk of a SDH to outweigh the benefit of anticoagulation with VKA.\(^{344}\) These overview calculations come with relevant limitations and it is uncertain if they translate into the current day situation. Nevertheless, given the even lower risk of intracranial bleeding compared with VKA, the ‘number needed to fall’ would be even higher with the use of NOACs.

The issue of falls in NOAC-treated patients was specifically analysed in subanalyses of two phase III trials. In the ENGAGE-AF TIMI 48 trial patients were prospectively classified as ‘high-’ or ‘low falls risk’ by the presence of known risk factors and co-morbidities.\(^{70}\) Patients at increased risk of falling were more likely to experience a bone fracture, major bleeding or life threatening bleeding, and death. Edoxaban was associated with reduced risk of severe bleeding, intracranial haemorrhage and the most severe net clinical benefit outcomes (secondary and tertiary net clinical outcome) compared to VKA in both patient categories, and the absolute risk reduction was greater with edoxaban in patients at increased risk of falling.\(^{70}\)

In the ARISTOTLE trial patients with a history of falling were older and more likely to have dementia and cerebrovascular disease. These individuals had an increased risk of major bleeding and intracranial bleeding as well as death, but the safety and efficacy of apixaban over warfarin was not affected by falling status.\(^{349}\) Among patients with a history of falls no subdural bleeding was recorded on apixaban.

This is also reflected in observational data indicating better outcomes on NOACs vs. VKA in patients at risk of falling.\(^{346–348}\) Caution is prudent, however, as more delayed intracranial haemorrhage in patients with a fall on NOACs has also been reported.\(^{349}\)

In summary, falling per se is not a contraindication to NOAC use (Table 14), but precautions should be taken and modifiable bleeding risk factors assessed (including, importantly, co-use of antiplatelet agents; see ‘Practical considerations for initiation and follow-up’ section). In addition, referral to a specialized falls assessment and intervention service should be offered to all patients to reduce risk of further falls.\(^{350}\)

**Cognitive impairment and dementia**

Mild cognitive impairment as well as dementia (cognitive impairment severe enough to compromise social and/or occupational functioning) is common in older age groups.\(^{351,352}\) AF itself is a risk factor for dementia and conversely, encouraging evidence indicates that OAC use may be associated with a reduced risk of dementia.\(^{353–357}\) This risk reduction may be similar with VKA and NOAC; however, long time in therapeutic range has been associated with dementia in VKA-treated patients.\(^{357–359}\)

Stroke as well as intracerebral haemorrhage are significant events for patients with dementia with a greater risk of cognitive and functional decline, loss of independence and institutionalization compared to non-dementia patients.\(^{360,361}\) AF in patients with dementia therefore requires similarly rigorous assessment for stroke prevention.

Dementia does pose unique considerations of adherence and safety when considering OAC. All patients with dementia should have a careful assessment of their ability to understand and make a treatment decision regarding OAC in AF, with indicative risks of stroke and bleeding provided. Where capacity is lacking, it may be reasonable for the physician to recommend treatment on the basis of the ‘best medical interest’ principle. This should be documented and explanation given to both patient and next of kin/legal attorney with assent/consent sought as relevant.

Adherence to OAC intake is of crucial importance. Both dementia and twice daily dosing has been shown to affect adherence with
as such, once daily medications, weekly tablet boxes, reminders or blister packing may be helpful (see ‘Practical considerations for initiation and follow-up’ section). Paradoxically, the fact that others may be supervising medication with dementia patients may guarantee higher adherence. Telemedicine to enhance treatment adherence in dementia and other assistive technologies may be useful in this population. It is advisable to re-assess cognitive function in older AF patients on a regular basis particularly considering and assessing their ability to adhere to the prescribed anticoagulation regimen.

**NOACs in high- and low body weights**

Weight and body mass index (BMI) are important variables in drug distribution and plasma concentration levels. Concerns exist in the absence of readily available measurements of anticoagulant effect that NOACs may not be as effective or safe at extremes of weight with a potential for both over- and underdosing. Weight or BMI was not an exclusion factor in the randomized NOAC-trials in AF (or VTE), although dose reductions for lower body weight (< 60 kg) were mandated for both apixaban (if also age > 80 years and/or creatinine > 1.5 mg/dL), and edoxaban.46–49

**NOACs in patients with high body weights**

**Effect of obesity on NOAC plasma levels**

Since 1975, obesity has tripled and the WHO now considers it an epidemic. In 2016, 1.3 billion adults were overweight (BMI of greater than 25 kg/m²) of which 650 million were obese (BMI greater than 30 kg/m²). Obesity increases both the risk of AF (possibly due to electro-modulation of the atrium) and risk of recurrent AF after successful ablation. Weight loss is an integral part of the multidisciplinary approach to prevention and treatment of patients with AF and obesity.70

Obesity affects the pharmacokinetics of drugs, including the volume of distribution (of lipophilic drugs in particular) as well as drug clearance. Renal blood flow and CrCl have been shown to be increased in obesity and could increase elimination of OACs. A number of studies of VKA have indicated that obese patients require greater doses and longer lead-in periods for achieving therapeutic INR values.73

Initial studies of dabigatran reported no effect of weight on pharmacokinetic variables although analyses in older healthy individuals did not include very obese patients. In the RE-LY trial, however, patients with a body weight >100 kg had 21% lower dose-normalized trough concentrations than patients with 50–100 kg body weight. The primary efficacy and safety outcomes were similar in patients with weight ≥ 100 kg vs. 50–99 kg vs. <50 kg (Ezekowitz et al., presented at ESC 2014). In the ENGAGE AF-TIMI 48 trial, no changes in plasma concentrations of edoxaban or its pharmacodynamic effect on FXa were observed between obese and normal weight patients.

**Efficacy and safety of NOACs in obese patients**

Concerns have been expressed about the reliability of the anticoagulant effect of NOACs in obese patients. In the RE-LY trial, no differences in the occurrence of stroke or systemic embolism were observed with dabigatran vs. warfarin in obese (≥100 kg) vs. non-obese patients. However, case reports of treatment ‘failure’ with low plasma levels of dabigatran have been reported in cases of severe obesity (BMI ≥ 40 kg/m²). Similar no differences were observed with apixaban vs. warfarin in obese patients (both as defined by BMI ≥ 40 kg/m² or 120 kg), rivaroxaban vs. warfarin (obesity defined as BMI ≥ 35 kg/m²), and edoxaban vs. warfarin (BMI > 40 kg/m²). However, only 620 patients from the ROCKET-AF trial had a very high BMI (≥40 kg/m²), and data from the RE-LY trial for dabigatran were not reported for this range. In contrast, 1003 and 1149 patients with a BMI ≥40 kg/m² were included in ARISTOTLE and ENGAGE AF-TIMI 48, respectively.

No difference in the occurrence of major bleeds were observed for dabigatran vs. warfarin, rivaroxaban vs. warfarin and edoxaban vs.
warfarin vs. non-obese patients. \(^{381,385,390}\) Relatively more major bleeds were observed with apixaban vs. warfarin in patients with a BMI \(\geq 30\,\text{kg/m}^2\) vs. lower BMIs as well as \(>120\,\text{kg}\) vs. \(<120\,\text{kg}\) although the incidence was still lower with apixaban vs. VKA even in obese patients. \(^{388,389}\)

Several studies from daily clinical practice indicated no substantially higher incidence in endpoints in obese vs. non-obese patients on NOACs. \(^{391}\) A systematic review and meta-analysis of the impact of weight on efficacy and safety of NOACs compared to VKA found overall better efficacy across all body weights (low, normal, overweight, obese) with no increased bleeding noted in low or obese categories, although the analysis had no additional high quality data other than the original four pivotal trials. \(^{392}\) Two small retrospective comparative studies found similar efficacy and safety in the NOAC group compared to VKA in the extreme obesity cohort; most data were available for apixaban and rivaroxaban, one reported numerically higher numbers of TIAs and stroke with dabigatran and neither study included data on edoxaban. \(^{393,394}\)

Based on the pharmacokinetic properties and the available evidence the use of all NOACs appears to be safe and effective up to a BMI of \(40\,\text{kg/m}^2\) (barring other clinically relevant factors). At BMI \(\geq 40\,\text{kg/m}^2\) data are less robust. \(^{381,385,388-390}\)

At a BMI \(\geq 50\,\text{kg/m}^2\) plasma level measurements with any of the NOACs (including the inherent associated limitations, see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section) or conversion to VKA therapy may be reasonable (Figure 23). Whether trough or peak plasma levels are preferable is a topic of further research; due to better reproducibility and correlation with clinical outcomes we generally advise for trough level measurement with peak level assessment only in selected cases.

**NOACs after gastric bypass surgery**

Treatment of obesity with bariatric surgery may have important effects on drug levels due to effects of surgery on the site and surface area of absorption, pH, blood flow, intestinal transit time, as well as the effect of post-operative restrictive diets. \(^{395}\) The location of the (presumed) major absorption site varies by anticoagulant but is thought to occur mainly in the proximal small intestine and, to a lower extend, in the distal stomach. \(^{396,397}\) The nature of gastric bypass surgery is also relevant whereby a concomitant bypass of the proximal small intestine may result in delivery of drugs to more P-gp rich distal segments and reduce overall absorption. \(^{398}\) VKA weekly dose-requirements are variable post bariatric surgery with most cases describing an initial decrease but subsequent steady rise in the post-acute phase of surgery. \(^{399-401}\) While cases of warfarin resistance post gastric-bypass procedure have been described, \(^{402}\) even large GI resections usually do not have a major lasting effect on warfarin anticoagulation. \(^{395}\)

Absorption of dabigatran may be affected (reduced) by higher pH and use of antacids (Table 4). \(^{403,404}\) While this is not considered relevant under normal circumstance it may play a role in patients after gastric bypass surgery. Bioavailability of rivaroxaban as used for stroke prevention in AF (20 mg, 15 mg) is increased by food, likely due to its lipophilicity and limited aqueous solubility, and administration of rivaroxaban distal to the stomach may lead to reduced absorption and rivaroxaban plasma levels. \(^{405,406}\) Hence, rivaroxaban (in the stroke prevention dose) may not be a preferred primary choice after gastric bypass surgery due to potentially relevant reductions in rivaroxaban exposure. \(^{398}\) One small study showed expected levels for dabigatran and apixaban but below-expected ranges for five of seven patients on rivaroxaban (including all four who had a gastric sleeve procedure). \(^{407}\) Edoxaban is highly and slightly soluble at acidic and neutral pH, respectively, and mainly absorbed in the proximal intestine. One study indicated that delivery directly to the distal intestine reduced both peak (Cmax) and total plasma levels (AUC). \(^{407}\)

Ultimately, the choice of anticoagulant post-bariatric surgery is a case by case consideration as strong clinical evidence is lacking, particularly for NOACs. As VKA appear least affected by gastric bypass surgery and target INR ranges are well-established, reverting to a VKA may represent a valid alternative. If use of a NOACs is considered necessary assessment of plasma levels (trough as well as peak levels) seems advisable (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section). This should be performed in the setting of a multidisciplinary team and at a centre with ample experience; in addition, several physiologic parameters are volatile after gastric bypass surgery such that repeated measurements over time may be required.

**NOACs in patients with low body weight**

There is no universal definition of low body weight although a BMI \(<18.5\,\text{kg/m}^2\) is considered by many western agencies as indicative of being underweight. \(^{408}\) Low body weight may increase exposure to any NOAC and as such increase the risk of bleeding compared to normal weight patients. \(^{409,410}\) Bleeding may also be increased with VKA therapy in underweight patients. \(^{410,411}\) Importantly, patients with low body weight frequently present with other conditions and co-morbidities which may increase the risk of stroke as well as bleeding, including old age, frailty, cancer, and CKD. Of note, renal function may be overestimated in underweight patients due to their reduced muscle mass (especially with the MDRD formula).

Special care is needed when anticoagulating low weight patients (Figure 23). Body weight \(<60\,\text{kg}\) requires dose reduction of apixaban [in patients with age \(\geq 80\,\text{years}\) and/or serum Creatinine \(>133 \mu\text{mol/l}\) (1.5 mg/dl)] as well as for edoxaban (see ‘NOAC eligibility and dosing’ section, Table 2), whereas it is in itself not a factor for dose reduction of rivaroxaban or use of lower dose dabigatran.

Both apixaban and edoxaban showed consistent efficacy and safety compared to warfarin in underweight patients when compared with the overall study population. \(^{98,381,389}\) Drug concentrations and inhibition of Factor Xa did not differ in patients with low body weight (range 30–55 kg) from patients with middle body weight in an analysis from ENGAGE AF-TIMI 48. \(^{382}\) As such, both drugs may be a preferred choice for patients \(<60\,\text{kg}\).

Dabigatran was studied post hoc in patients with low body weight \((<50\,\text{kg})\) with consistent efficacy compared with the remainder of the study cohort but a signal for increased bleeding events in patients with a lower BMI (particularly \(<20\,\text{kg/m}^2\); Ezekowitz et al., presented at ESC 2014). \(^{48}\) Observational studies have equally suggested that low BMI may be an independent predictor of bleeding events with dabigatran and a trend to greater bleeding was noted with high dose dabigatran in a meta-analysis of low weight patients. \(^{392,412}\) Frequently co-existing CKD may also make it a less preferable option for underweight patients.
Rivaroxaban showed similar efficacy and safety in an exploratory analysis of the ROCKET-AF trial for lower body weight, but only patients <70 kg were compared with those >70 kg. No specific outcome data was available for patients with <60 kg or <50 kg in patients on the full AF dose of rivaroxaban. Subsequent meta-analyses and observational data are reassuring with regard to safety in low and severely underweight patients (<50 kg), but limitations (residual confounding in particular) persist.\(^{392,413}\)

If therapy with a NOAC is warranted in low and very low weight individuals, measurement of trough levels may be considered to check for accumulation of the drug.\(^{414}\) However, no evidence-based recommendations can be given regarding (further) dose reduction in cases where trough levels are above the expected range (see ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section).

### NOACs in other special populations

Special considerations for the use of NOACs in athletes and women of reproductive age are discussed in the Supplementary material online.

### Epilepsy and NOACs

#### Scope of the problem

Epilepsy can have both genetic and acquired causes, the latter including brain trauma, stroke, tumours and brain infections. Epilepsy after a stroke is not an uncommon finding.\(^{419}\) Risk of seizures is reported between 7% and 11.5% overall post-stroke and in 3–6% of cardioembolic stroke.\(^{416–420}\) Incidence of recurrent unprovoked seizure post-stroke may be as high as 71% and prevention of such events using antiepileptic drugs (AEDs) is desirable especially when patients are on OAC.\(^{421–423}\) Many features of AF-associated stroke such as cortical involvement, cerebral artery territory, multiple infarcts, severe deficit and haemorrhagic transformation are also predictive of developing post-stroke epilepsy.\(^{424,425}\)

OAC poses a special risk for patients with epilepsy. While most seizures in older people and post-stroke are focal in onset, patients who suffer seizures without aura or rare tonic seizures are particularly vulnerable to head trauma. Tongue biting is a risk in the tonic component of generalized seizures.

#### Potential drug–drug interactions

Many AEDs relevantly induce hepatic enzymes (e.g. ethosuximide carbamazepine, phenobarbital, phenytoin, primidone) or are mild inducers (e.g. oxcarbazepine, lamotrigine, tiagabine) thereby potentially reducing the efficacy of VKAs as well as certain NOACs (Table 7). Other AEDs inhibit hepatic metabolism (felbamate, topiramate, valproate, vigabatrin) and can increase the risk of bleeding with VKAs. Valproate may have unpredictable effects on CYP3A4.\(^{426}\) Conversely, animal and/or human studies have indicated that carbamazepine, levetiracetam, phenobarbital, phenytoin and valproic acid may decrease the effect of NOACs by inducing P-gp activity. Newer third generation AEDs such as brivaracetam, lacosamide and eslicarbazepine may have less potential for DDI.\(^{427}\) In addition, AEDs can have an indirect effect on the coagulation system, e.g. by causing thrombocytopenia or platelet dysfunction.\(^{428}\)

Sporadic case reports exist about DDIs between NOACs and AEDs (Table 7).\(^{429,430}\) The majority of DDIs to date have cited reduced efficacy of NOACs due to these mechanisms.\(^{431}\) One series reported an increased bleeding risk with phenytoin.\(^{432}\) Another retrospective cohort of patients from Taiwan on NOACs and 11 different AEDs reported increased association of bleeding with concomitant prescription of phenytoin, valproic acid or levetiracetam but this may not be generalizable to other populations.\(^{433}\) After inquiry with the drug manufacturer there is unfortunately no study which reliably investigated the effect of levetiracetam on NOAC plasma levels and clinical events in a sufficiently large ‘real world’ cohort of concomitantly treated patients. We strongly advise such studies should be conducted (not only with levetiracetam, but also with other AEDs) in order to better enable clinical decision-making in this difficult to treat patient population.

#### Practical advice

Robust evidence is lacking for DDI with NOACs and AEDs and there is poor concordance in international drug compendia on the subject.\(^{434}\) Where AED therapy is desirable in AF patients with epilepsy treated with a NOAC vigilance for potential DDI is warranted (see ‘Pharmacokinetics and drug–drug interactions of NOACs’ section) and regular interdisciplinary review with the treating cardiologist, neurologist, primary care physician, and clinical pharmacist is crucial. Especially in the context of comedication with anti-seizure drugs, NOAC plasma level measurements are frequently proposed, similar to plasma-level guided dosing of anticonvulsants.\(^{435–438}\) However, as indicated and discussed in the ‘NOAC plasma level measurements: technical approach, indications, pitfalls’ section—and in contrast to the situation with anti-epileptic drug level measurements—such an approach is without any endpoint-derived clinical trial evidence, especially with respect to dosing NOACs according to their measured levels.\(^{433,438}\) Therefore, such patients should be treated at expert centres with extensive experience in the measurements of NOAC plasma levels and their interpretation.

### NOACs in Asians and other non-Caucasian ethnicities

In the past, ethnicity has been shown to be a factor in VKA underuse, poor INR control, and increased stroke- and death rates in non-White vs. White populations.\(^{439–442}\) Differences in body mass, genetic polymorphisms of the cytochrome P450 system affecting drug metabolism have been suggested as relevant factors for this difference impacting on efficacy and safety of stroke prevention in AF. Environmental factors around diet and lifestyle, socioeconomic and educational status are important confounders which are not always easy to separate from biological effects.\(^{443–446}\) Concerns are nonetheless frequently raised that the outcomes observed in the large NOAC trials might not be generalizable to all ethnicities encountered in daily clinical practice.

All four phase III trials of dabigatran, rivaroxaban, apixaban, and edoxaban in AF included a predominantly white population, i.e. 70%, 82.9%, 62.7%, and 76.5%, respectively. While the number of Asian patients who were enrolled was relatively large (16%, 12.7%, 14.5%, 20.8% and 12.1%), respectively, there is a lack of appropriate data in non-Asian populations. Due to the lack of large, well-powered trials harnessing NOACs in non-White populations the clinical implications of this differential patient population are not fully understood.
and 13.6% in RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE AF-TIMI 48, respectively) a relatively lower number of Hispanic (6.9%, not reported in ROCKET-AF, 19.8% and 12.4%, respectively) and a much lower percentage of Black patients (1%, 1.3%, 1.2%; not reported in ENGAGE AF-TIMI 48) was included.46–49

NOACs in Asians

Overall, Asians are a very diverse ethnic group. Asian patients are at an increased risk for both stroke and bleeding. Indeed, recent data suggests that the risk of stroke may rise from age 50–55 years upwards and that a modified CHA2DS2-VASc score may need to be used in Asian patients.1,446–448 In VKA users, efficacy for the prevention of ischaemic strokes was shown to be lower and the risk of intracerebral haemorrhage higher in Asian- vs. non-Asian patients, possibly linked to a lower TTR combined with more frequent non-cardioembolic stroke sources. Asian ethnicity may also have an impact on metabolism and clearance of NOACs, trough concentrations and anti-FXa activity due to lower body weight and increased rates of renal disease thereby potentially limiting the ability to simply extrapolate data from Caucasians.451,452

Across the four phase III NOAC trials >8600 Asian patients were included. As in previous studies, rates of intracranial haemorrhage as well as ischaemic stroke were higher in Asians as compared to non-Asians.452–455 The reduction in major (especially intracranial) bleeding was at least as pronounced if not greater with NOACs vs. VKA in Asians indicating a possibly even greater safety advantage as compared to non-Asian patients.450,452–455 In addition, and importantly, there were no signs for a reduced efficacy in the prevention of stroke and systemic embolism across the approved NOAC regimens. These findings were largely confirmed in observational registries.55,456,457

Taken together, these data indicate that NOACs may represent a preferred option for anticoagulation also in Asian patients.450,452 which may also extend to Asian patients with low body weight.413

Black, Hispanic, and other ethnicities

Black patients have been shown to have a lower incidence of AF but appear to be at higher risk of stroke.458–460 The rate of stroke in AF equally appears higher and outcomes may be worse in Hispanics vs. non-Hispanic patients.461,462 As such, also these patients would be of particular interest regarding their outcome on NOACs, yet (as indicated above) the number of Black and Hispanic patients included into the four landmark NOAC trials was relatively low.

Subanalyses for ethnicities showed
- Dabigatran (RE-LY):
  - Preserved efficacy and reduced incidence of ICH across ethnicities compared to VKA.48,453
  - Efficacy and safety vs. warfarin preserved in patients included in Latin America.463
- Rivaroxaban (ROCKET-AF):
  - Efficacy and safety vs. warfarin similar across ethnicities and regions of inclusion.16
  - Reduced incidence of ICH vs. VKA in all ethnicities (with higher rates of ICH in Blacks compared to Whites).464
- Apixaban (ARISTOTLE):
  - No difference for patients included in Latin America as compared to North America or Europe regarding efficacy and safety vs. VKA.47
  - Risk of ICH higher in patients included in Latin America vs. Europe.283
- Edoxaban (ENGAGE AF-TIMI 48):

Figure 24 NOACs in patients with thrombocytopenia. NOAC, non-vitamin K antagonist oral anticoagulant.
Higher risk of ICH in Latin American patients compared to Non-Latin American patients.465

Significant reduction in ICH in both populations on edoxaban vs. VKA.465

In totality, these data hence indicate that NOACs should also be the preferred therapy for Black or Hispanic patients, particularly due to the oftentimes difficult and suboptimal alternative of VKA therapy (which may at least in part be due to confounding, as indicated above). However, and similar to all other settings (see ‘Practical considerations for initiation and follow-up’ section), measures to improve care including an increase in the awareness of the disease and its consequences, optimal control of comorbidities (particularly blood pressure, diabetes, etc.), frequent medication review and careful assessment for dose reduction criteria are crucial to realize the advantages in daily clinical care. In addition, these findings also indicate the clear necessity for more high-quality data to better understand the efficacy and safety profile of NOACs in diverse ethnic populations.

Patients with thrombocytopenia

NOAC therapy in thrombocytopenia

Platelet count <100 × 10^3/L was an exclusion criterion in the RE-LY (dabigatran vs. VKA) and ENGAGE AF-TIMI 48 trials (edoxaban vs. VKA) and a count <90 × 10^3/L in the ROCKET-AF trial (rivaroxaban vs. VKA) in AF.46,48,49 Thrombocytopenia was not a listed exclusion factor in the ARISTOTLE trial of apixaban vs. VKA in AF.47 Patients with platelet counts as low as 50 × 10^3/L were included in trials of edoxaban and rivaroxaban,46,47 and 75 × 10^3/L for apixaban in treatment of cancer-related VTE.468

Observational data indicate that NOACs are associated with a similar rate of ischaemic stroke and systemic embolism and a lower incidence of bleeding than VKA in thrombocytopenic AF-patients.469 A small prospective study looking at patients with AF and mild thrombocytopenia (50–100 × 10^3/L) on reduced dose dabigatran (110 mg BID), apixaban (2.5 mg BID), and rivaroxaban (15 mg QD) found no difference in the rates of major bleeding or ischaemic stroke compared to patients with normal thrombocyte count on the recommended doses of those agents.470

Table 15 Maintenance warfarin dosing for out-of-therapeutic-range international normalized ratio

<table>
<thead>
<tr>
<th>INR</th>
<th>Dose adjustment per week</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤1.5</td>
<td>↑ by 15%/week</td>
</tr>
<tr>
<td>1.6–1.9</td>
<td>↑ by 10%/week</td>
</tr>
<tr>
<td>2–2.9</td>
<td>Unchanged</td>
</tr>
<tr>
<td>3–3.9</td>
<td>↓ by 10%/week</td>
</tr>
<tr>
<td>4–4.9</td>
<td>Hold 1 dose, then restart with dose ↓ by 10%/week</td>
</tr>
<tr>
<td>≥5</td>
<td>Hold until INR is 2–3, then restart with dose ↓ by 15%/week</td>
</tr>
</tbody>
</table>

Suggested dose adjustment in case of out-of-therapeutic-range INR.556 Importantly, dosing is optimized not using daily dose adjustments but adjustments based on the weekly intake in warfarin.

Figure 25 Important aspects in the management of AF patients with malignancies. AF, atrial fibrillation; LMWH, low molecular weight heparin; NOAC, non-vitamin K antagonist oral anticoagulant; PPI, proton pump inhibitor; VKA, vitamin K antagonist.
There is no ‘safe’ cut-off above which NOAC therapy is without risk in patients with thrombocytopenia. In addition to the absolute number of platelets the dynamics of the platelet count, the underlying reason for thrombocytopenia, and special risk factors (including the likelihood of dysfunctional platelets as well as other coagulation abnormalities) need to be considered.471 Our general advice is summarized in Figure 24. Given the lack of a large evidence base for guidance the decision for NOAC treatment needs to follow an individualized, team-based approach including the patient and his/her needs and expectations (shared decision-making).

NOACs and heparin-induced thrombocytopenia
Thrombocytopenia is listed in the individual SmPCs as ‘uncommon’ (>1/1000 to <1/100 patients) as a side effect of NOACs,403,405,472,473 but isolated cases have been reported.474–479 In heparin-induced thrombocytopenia ± thrombosis (HIT/HITT) there is growing evidence that NOACs are not recognized by pre-existing HIT antibodies, do not complex with platelet factor 4 and do not cause platelet aggregation.480–482 NOAC therapy may hence constitute a viable less expensive and easier to administer alternative to parenteral heparin substitutes (e.g. argatroban, fondaparinux) especially if the latter are not available or are deemed unsuitable.483,484 Further research is required in this field to confirm and strengthen these first positive experiences.

NOACs in patients with atrial fibrillation and malignancy
The scope of the problem
Cancers are not infrequent in older patients, similar to AF.485 Cancer and cancer therapy may in turn precipitate AF, while both age and malignancy are independent risk factors for thrombosis and bleeding. The scope of the problem of AF and malignancy is outlined in detail in the Supplementary material online.

Anticoagulant therapy in patients with malignancy
In the phase III VTE trials specifically targeting cancer patients, edoxaban (Hokusai Cancer),466 rivaroxaban (Select-D),467 and apixaban (Caravaggio)486 were non-inferior to dalteparin in the prevention of recurrent VTE. While there was a signal of improved efficacy with both edoxaban and rivaroxaban vs. dalteparin, bleeding tended to be higher with the two NOACs as compared to dalteparin, which was driven mainly by patients with GI cancers. For apixaban, efficacy and safety were broadly similar between the NOAC and LMWH.

Concerning the prevention of stroke and systemic embolism in AF patients with cancer, available evidence is less strong, as active malignancy was an exclusion criterion in most NOAC AF Phase III trials. In a recent meta-analysis487 of five studies (post hoc analyses of the ROCKET AF,488 ENGAGE AF-TIMI 48,489 and ARISTOTLE490 trials, and two retrospective population-based cohorts),489,491 the use of NOACs compared to warfarin was associated with a significantly reduced risk of stroke, systemic embolism, and VTE, a strong trend towards fewer ischaemic strokes (P = 0.05) and a numerically lower incidence of MI, all-cause mortality and cardiovascular death. There was a strong trend towards fewer major bleedings (P = 0.05), significantly fewer intracranial or GI bleedings, and a comparable number of clinically relevant major or non-major bleeds with NOACs. Pooling the three post hoc studies showed similar rates of efficacy and safety outcomes with NOACs vs. warfarin in AF patients with and without cancer.

A large registry using a prescription-based analysis for AF patients on VKA or NOAC with and without cancer reported equivalence for bleeding and thromboembolic incidence and cancer status, although the rates of both were lower in the NOAC population.493 However, much is still unknown about DDIs between NOACs and specific chemotherapeutic agents, urging further caution (Table 6).494

Overall, anticoagulation with NOACs may appear as a valid option in patients with AF and malignancy based on the few available data from RCTs as well as using extrapolations from cancer-related VTE treatment. Antithrombotic therapy in patients with AF suffering from a malignancy needs a dedicated interdisciplinary team approach (Figure 25).495 Especially when myelosuppressive chemotherapy or radiation therapy is planned, temporary dose reduction or cessation of NOAC therapy needs to be evaluated, taking into account full blood counts including platelets, renal/liver function, and physical signs of bleeding. Gastric protection with PPI or H2 blockers should be considered in all such patients.

Optimizing dose adjustments of vitamin-K antagonists
Specific considerations for optimizing dose adjustments of VKA are discussed in the Supplementary material online. One algorithm to optimize VKA dosing is presented in Table 15, derived from the warfarin arm of the RE-LY trial.556

Supplementary material
Supplementary material is available at Europace online.

Acknowledgements
The authors thank the EHRA Scientific Document Committee: Dr Nikolaos Dagres, Prof. Thomas Denke, Prof. Arthur Wilde, Prof. Frank R. Heinzel, Prof. Christian Meyer, Prof. Lucas Boersma, Prof. Radoslaw Lenarczyk, Prof. Luigi Di Biase, Dr Elena Arbelo, Dr Avi Sabbag, Prof. Pierre Jais, Prof. Milos Taborsky, and Associate Prof. Markus Stühlinger.

Funding
This article and derived educational materials (slide set, website, booklet, and NOAC card) were produced by and under the sole responsibility of the European Heart Rhythm Association, and supported by Bayer Pharma AG, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Daiichi-Sankyo Europe GmbH in the form of an Unrestricted Educational Grant.

Conflict of interest: JS has received consultant and / or speaker fees from Abbott, Amgen, Astra-Zeneca, Bayer, Berlin-Chemie, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medscape, Medtronic, Merck/MSD, Novartis, Portola, Roche Diagnostics, Pfizer, Portola, Saja, Servier, and WebMD. He reports ownership of CorXL. JS has received grant support through...
his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, and Medtronic. RC has received speakers honoraria from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer. MA reports personal fees from Bayer, Biosense Webster, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer; and fees to his institution from Abbott, Bayer, Berlin-Chemie, Biosense Webster, Biotronik, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Novartis, Medtronic, Pfizer and Sanofi Aventis. KGH reports a study grant by Bayer, lecture fees/advisory board fees from Abbott, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Medtronic, Pfizer, Premier Research, and W. L. Gore & Associates. JO reports fees to his institution from Alexion, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Pfizer, Roche Diagnostics, and Sanofi. HR reports personal fees from Daichi, Pfizer, MedUpdate, DiaPlan, NeoVasc, Pluristem, NovoNordisk and Corvia. Furthermore, grants were received from Pluristem, BMS, Pfizer, Bard and Biotronik. NR reports personal fees from Bristol-Myers Squibb and Pfizer. PS reports small institutional speaker/s/ advisory fees from Daichi Sankyo, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Sanofi Aventis, and Leo Pharma. TP reports consultancy for Bayer and Pfizer (no fees). AGC reports personal fees from Bayer, Daiichi Sankyo and Pfizer/BMS. HH reports minor personal honoraria from BMS, Pfizer, Biotronik and Daiichi-Sankyo and received unconditional research support through the University of Antwerp or University of Hasselt from Bayer, Daiichi-Sankyo, Boehringer-Ingelheim, Bracco Imaging Europe, Medtronic, Boston-Scientific, Biotronik, and St. Jude Medical, PC, LD and VRS declare that they have nothing to disclose.

References


482. Walenga JM, Prechel M, Jeske WP, Hoppensteadt D, Maddineni J, Iqbal O et al. 


489. Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA et al. 

490. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA et al. 

491. Kim K, Lee YJ, Kim TH, Uhm JS, Pak HN, Lee MH. 

492. Kim K, Lee YJ, Kim TH, Uhm JS, Pak HN, Lee MH. 

493. Hu YF, Liu CJ, Chang PM, Tsao HM, Lin YJ, Chang SL. 


496. European Medicines Agency. 


Downloaded from https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euab065/6247378 by guest on 28 April 2021


